MXPA01005635A

MXPA01005635A - New b-amide and b-sulfonamide carboxylic acid derivatives, their preparation and their use as endothelin receptor antagonists

Info

Publication number: MXPA01005635A
Application number: MXPA/A/2001/005635A
Authority: MX
Inventors: Amberg Wilhelm; Jansen Rolf; Hergenroder Stefan; Raschack Manfred; Unger Liliane; Kettschau Georg; Riechers Hartmut; Baumann Ernst
Original assignee: Abbott Gmbh&Ampco Kg
Priority date: 1998-12-18
Filing date: 2001-06-05
Publication date: 2001-12-04

Abstract

The invention relates to carboxylic acid derivatives of formula (I), in which the substituents have the following meanings:R1 is tetrazol or a group (a);W and Z, can be identical or different and are nitrogen or methine, provided that if W and Z are methine, then Q is nitrogen;X is nitrogen or CR9;Y is nitrogen or CR10;Q is nitrogen or CR11, provided that if Q is nitrogen then X is CR5 and Y is CR10;R2 and R3 are identical or different and are possibly substituted phenyl or naphthyl or phenyl or naphthyl which are linked in an ortho position via a direct bond, a methlyene, ethylene or ethenylene group, an oxygen or sulfur atom or a SO2-, NH- or N-alkyl group or possibly substituted C5-C6-cycloalkyl;R4 is a rest (b) or (c);and R5 is hydrogen, C1-C4-alkyl. The invention further relates to their preparation and their use as endothelin receptor antagonists. The invention also relates to compounds of formula (II) and a structural fragment of formula (d) in which the rests R1, R2, R3, R4 and R5 have the meanings given in claim no. 1 and to their use as structural elements in an endothelin receptor antagonist.

Description

Novel β-amido and β-sulfonamido carboxylic acid derivatives, their preparation and use as endothelin receptor antagonists The present invention relates to novel carboxylic acid derivatives, their preparation and use. Endothelin is a peptide that comprises 21 amino acids and is synthesized and released by the vascular endothelium. Endothelin exists in three isoforms, ET-1, ET-2 and ET-3. "Endothelin" or "ET" refers to one or all of the endothelin isoforms. Endothelin is a potent vasoconstrictor and has a strong effect on vascular tone. It is known that this vasoconstriction is caused by the binding of endctelin with its receptor (Nature, 332, 411-415, 1988, FEBS Letters, 231, 440-444, 1988 and Biocheir .. Biophys. Res. Commun., 154, 868-875, 1988). A high or abnormal release of endothelin causes a persistent vasoconstriction in peripheral blood vessels, kidney and brain, which can result in disorders. As reported in the literature, endothelin is involved in numerous conditions. These include: hypertension, acute myocardial infarction, pulmonary hypertension, Raynaud's syndrome, cerebral vasospasm, stroke, benign prosthetic hypertrophy, atherosclerosis, asthma, and prostate cancer (J. Vascular Med. Biology, 2, 207 (1990), J. Am. Med. Association 264, 2868 (1990), Nature 344, 144 (1990), N. Engl. J. Med. 32J2, 205 (1989), N. Engl.- J.

Med. 328, 1732 (1993), Nephron 66, 373 (1994), Stro e 25, 904 (1994), Nature 365, 759 (1993), J. Mol. Ceil. Cardiol. 2 A234 (1995); Cancer Research 56, 663 (1996), Nature Medicine 1, 944 (1995)). At least 2 subtypes of endothelin receptors, the ETf receptors. and TEE are now described in the literature (Nature 348, 730 (1990), Nature 348, 732 (1990)). Therefore, substances that inhibit the binding of endothelin to one or both receptors must antagonize the physiological effects of endothelin and therefore represent valuable drugs. Document IEE 19726146.9 describes the preparation. of ß-amir.o and ß-azido derivatives of carboxylic acid and their use as antagonists of endothelin receptors. In addition, research has revealed that related aromatic carboxamides and sulfonamide derivatives have beneficial properties with respect to receptor affinity and receptor binding profile. The present patent relates to the preparation and thereof. The present invention relates to β-amido and ii-sulphonamido carboxylic acid derivatives of the formula I wherein R * is tetrazolyl or a group OR II C-R b wherein R has the following meaning: a) a radical 0R, wherein Rc is: hydrogen, the cation of an alkali metal, the cation of an alkaline earth metal or an organic or physiologically tolerable ammonium ion, for example icr. alkylammonium C_-C? tertiary or ammonium ion; C_-C = cycloalkyl, C-C-Ce alkyl, phenyl-CH_, which may be substituted by one or more of the following radicals: halogen, nitro, cyano, C-C, alkyl, haloalkyl C.-C. :, hydroxyl, C.sub.1 -C. alkoxy, ercapto, C.sub.12 alkylthio, amino, NH (C.sub.C alkyl), N (C.sub.1 -C.sub.alkyl); an alkenyl group C_ < -C. or a C-C- alkynyl group, it being possible for these groups to in turn carry from one to 0 five halogen atoms; R ° may furthermore be a phenyl radical which may carry from one to five halogen atom and / or one to three of the following radicals: nitro, cyano, C-C alkyl, haloalkyl C_-C4 hydroxyl, alkoxy C -.- C , mercapto, alkylthio C.-C-, amino, NH (alkyl C_-C_), N (alkyl C_- C < ) _; a 5-membered heteroaromatic system linked through a nitrogen atom, such as, for example, pyrrolyl, pyrazolyl, imidazolium and triazolyl, which may have one or two halogen atoms or one or two C: -C alkyl groups or two C: -C alkoxy groups; a group wherein k can take the values C, i and 2, p can take the values 1, 2, 3 and 4, and R is C 1 -C 4 alkyl, C -d cycloalkyl, C alkenyl, C 1 -C 4 alkynyl C; c phenyl, which may be substituted by one or more, for example, one or three of the following radicals: halogen, nitro, cyano, C-C4 alkyl, hydroxyl, C: -C4 alkoxy, alkylthio C-C- , amino, NH, alkyl C -.- C), N (C -.-C. Alkyl);, mercapto; a radical O II -N S Rß H or II wherein Rd is: C1-C4 alkyl, C3-C3 alkenyl, C3-C9 alkynyl, C3-C0 cycloalkyl, it being possible for these radicals to carry a C?-C4 alkoxy radical, Cilt-C alkylthio. and / or a phenyl radical according to what is mentioned in c); Ci-C4 haloalkyl or phenyl, unsubstituted or substituted in particular as mentioned in c). The other substituents have the following meanings: and Z, which may be identical or different are: nitrogen or methine; provided that Q = nitrogen if W and Z = methine; X is nitrogen or CR9; And it is nitrogen or CRlC; Q is nitrogen or CR11; provided that X = CR; * and Y = CRl? if Q = nitrogen; R ~ and R ", which may be identical or different, are: phenyl or naphthyl, each of which may be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, mercapto, alkyl C_- C4 , C2-C-alkenyl, C-C-alkynyl, C4-haloalkyl, C1-C4-alkoxy, phenoxy, C-C4-haloalkoxy, C-C4-alkylthio, amino, NH (C? -C alkyl), N- (C1-6 alkyl) C4): or phenyl which can be substituted one or more times, for example one to three times, by halogen, nitro, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C: -C4 alkoxy, haloalkoxy C: -C4 or alkylthio C.-C4; either fer.yl or naphthyl joined together in ortho positions by a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or a S0_, NH or N-aikyl group; C5-C- cycloalkyl, it being possible for these radicals to be substituted once or several times by: halogen, hydroxyl, mercapto, carboxy, nitro, cyano, C? -C4 alkyl, C-C alkenyl, C-alkynyl; -C, alkoxy C: -C_, alkylthio C.-C :, halcalkoxy C: -C_; a) a radical wherein R "is phenyl, naphthyl or a five or six member heteroaromatic system comprising one to three nitrogen atoms and / or a sulfur atom or oxygenate, it being possible for said radicals to be replaced once or several times by: halogen, nitro, cyano, hydroxy, mercapto, Ci-C-alkyl, C-C-hydroxyalkyl, C-C4-haloalkyl, C-C4-alkoxy, C-C4-alkylcarbonyl, carboxyl, C-C-haloalicyloxy, C-C-alkylthio , amino, NH (C: -C4 alkyl). N (C: -C4 alkyl) :, HNSOc, (C_-C4 alkyl); H; NSO;, (C -.- C) alkyl .NSO_, or phenoxy or phenyl, each of which may be substituted one or several times, for example, from one to three times, by halogen, nitro, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C alkoxy, C 1 -C 6 haloalkoxy and / or C 1 alkylthio; ~ C b) a radical OR II S - R " wherein R- 'is alkyl C? -C, haloaicyl C.-C, or phenyl being possible that the phenyl radical in turn carries from one to five halogen atoms and / or from one to three atoms of the following radicals : C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 4 -C 4 alkoxy, C 0 -C haloalkoxy and / or C 1 alkylthio R ~ is hydrogen, C? -C4 alkyl; R 'and Riü (which may be identical or different) are: hydrogen, halogen, C -.- C4 alkoxy, haloalkoxy C.-C, alkenyloxy C-; - C ^, alkynyloxy C_-C, alkylthio C.-C; , C1-C4 alkylcarbonyl, C: -C alkoxycarbonyl, hydroxyl, NH 2, NH (C 1 -C 4 alkyl), N (C 1 -C 4 alkyl); C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, it being possible for these radicals to be substituted by halogen, hydroxyl, mercapto, carboxyl , cyano; either CR9 or CR10 is linked with CR1"in accordance with that indicated for R11 to provide a 5- or 6-membered ring, R11 is hydrogen, halogen, C?-C4 alkoxy, C_-C4 haloalkoxy, C3-C3 alkenyloxy, alkynyloxy C-C, alkylthio C: -C, C 1 -C 4 alkylcarbonyl, C 4 -C 4 alkoxycarbonyl, NH (alkyl) C? -C < ), N (C 1 -C 4) alkyl, hydroxyl, carboxyl, cyano, amino, mercapto; C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, it being possible for these radicals to be replaced one or more times by: halogen, hydroxyl, mercapto, carboxyl, cyano, amino, C 1 -C 4 alkoxy; or CR11 forms together with CR9 or CRi0 a 5 or 6 membered alkylene or alkenylene ring, which may be substituted by one or two C1-C4 alkyl groups, and wherein in each case one or more methylene groups may be replaced by oxygen, sulfur, -NH or - N (C_-C4 alkyl). The definitions that apply here and below are: an alkali metal is, for example, lithium, sodium, potassium; an alkaline earth metal is, for example, calcium, magnesium, barium; Organic ammonium ions are protonated amines such as ethanolamine, diethanolamine, ethylenediamine, diethylamine or piperazine; C3-C0 cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; C4-C4 haloalkoxy can be linear or branched, for example, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorodifluoromethyl, trichloromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2- chloro-2, 2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl or pentafluoroethyl; C1-C4 haloalkoxy may be linear or branched, for example, difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, 1-fluoroethoxy, 2,2-difluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro -l, 1,2-trifluoroethoxy, 2-fluoroethoxy, or pentafluoroethoxy; C 1 -C 4 alkyl can be linear or branched, for example, methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl or 2-butyl; C2-C4 alkenyl may be linear or branched, for example, ethenyl, l-propen-3-yl, l-propen-2-yl, 1-propen-l-yl, 2-methyl-1-propenyl, 1-butenyl or 2-butenyl; C2-C4 alkynyl can be linear or branched, for example, ethynyl, 1-propyn-l-yl, l-propyn-3-yl, l-butin-4-yl or 2-butin-4-yl; Ci-C4 alkoxy can be linear or branched, for example, methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1, 1-dimethylethoxy; C3-C0 alkenyloxy may be linear or branched, for example, allyloxy, 2-buten-l-yloxy or 3-buten-2-yloxy; C3-C6 alkynyloxy may be linear or branched, for example, 2-propy-1-yloxy, 2-butyne-1-yloxy or 3-butyne-2-yloxy; alkylthio C: -C can be linear or branched, for example, methylthio, ethylthio, propylthio, 1-methylethiithio, butylthio, 1-methylpropylthio, 2-methylpropylthio or 1,1-dimethylethylthio; C1-C5 alkylcarbonyl can be linear or branched, for example, acetyl, ethylcarbonyl or 2-prp-p-carboncarbon; C1-C alkyl & it can be linear or branched, for example C 1 -C 4 alkyl pentyl, hexyl, heptyl or octyl; C3-C alkenyl. it can be linear or branched, for example, 1-propen-3-yl, l-propen-2-yl, 1-propen-1-yl, 2-methyl-1-propenyl, 1-buten-4-yl, 2 -buten-3-yl, l-penten-5-yl, 1-hexen-6-yl, 3-hexen-6-yl, 2-hepten-7-yl or l-octen-8-yl; C_-C = alkynyl can be linear or branched, for example, 1-propin-1-yl, l-propin-3-yl, l-butin-4-yl, 2-butin-4-yl, l-pentin- 5-yl, 3-hexin-6-yl, 3-heptin-7-yl or 2-octin-8-yl; Halogen is, for example, fluorine, chlorine, bromine, iodine.

The invention further relates to the compounds from which the compounds of the formula I can be released (known as prodrugs). Preferred prodrugs with prodrugs whose release is effected under conditions prevailing in certain compartments of the body, for example, in the stomach, intestine, blood circulation, liver. The compounds I and the intermediates for their preparation, for example, II and III, may have one or more atoms asymmetrically substituted. Compounds of this type can exist as pure enantiomers either as pure diastereomers or as a mixture thereof. It is preferred to employ an enantiomerically pure compound as the active ingredient. The invention further relates to the use of the above-mentioned carboxylic acid derivatives to produce drugs, particularly to produce inhibitors of ETA and / or TEE receptors. The novel compounds are suitable as antagonists in accordance with that defined at the beginning. The compounds according to the invention according to I can be prepared by the routes described in DE 19726146.9. A possible alternative to this is the preparation through intermediates of the general formula III; these derivatives can be synthesized either through the reduction of azides of the formula II (cf. DE 19726146.9) by generally known methods or by the opening of the oxazoline derivatives of the general formula IV which are described in WO 95/07266.

The cxazoline derivatives of the formula IV can be opened by treatments with aqueous solutions of strong acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, perchloric acid, tnfluoroacetic acid, toluenesulfonic acid, methanesulfonic acid or trifluoromethanesulfonic acid in the presence of a solubilizer. suitable. All miscible solvents er. Water can be used for this purpose insofar as they are inert in relation to the reagents used. Examples of such solubilizers are alcohols such as methanol, ethanol, n-propanol, isopropanol, ethers such as tetrahydrofuran or dioxin; nitriles such short acetonitrile or propionitrile; amides such as dimethylformamide or dimethylacetamide; sulfoxides and sulfones such as dimethyl sulfoxide; carboxylic acids such as acetic acid or propionic acid. The reaction to this case is preferably carried out at a temperature within the range of 0 ° C to the boiling point of the solvent or mixture of solvents. Compounds according to the invention can be prepared wherein RR "N is aromatic or heteroaromatic carboxamide, for example, by acylation of III on nitrogen, or alternatively, during the acylation of both the amino group and the hydroxyl group on III and then by eliminating the acyl ester group using generally known methods For this purpose, the compound of the general formula I reacts with the acylating agent in the molar ratio 1: 6 in the presence of a suitable diluent. Solvents that are inert with respect to the reactants used can be used for this purpose.

III V Examples of such solvents or diluents are aliphatic, alicyclic and aromatic hydrocarbons, which may in each case optionally be chlorinated, such as, for example, hexane, cyclohexane, petroleum ether, naphtha, benzene, toluene, xylene, methylene chloride, chloroform, ethyl chloride and trichlorethylene, ethers such as diisopropyl ether, dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran, nitriles such as acetonitrile and propioritrile, amides such as dimethylformamide, dimethylacetamide and N-methylpyrrolidone, sulfoxides and sulfor. such as dimethyl sulfoxide and sulfolane. The reaction in this case is preferably carried out at a temperature within a range between C ° C and the boiling point of the solvent or mixture of solvents. The presence of a reaction catalyst can be advantageous. A suitable catalyst in this case is, for example, dimethylaminopyridine. The resulting compounds of the general formula V are converted to the β-amido carboxylic acid derivatives according to the invention by the reaction of the compounds of the general formula V with heterocycles of the general formula VI. R * the R14 in formula VI is halogen or R1 = -S0-, where R15 can be C4-C4 alkyl, C: -Ci haloalkyl or phenyl, and the definitions of W, X, Y, Z and Q are the definitions provided at the beginning. The reaction is preferably carried out in an inert solvent or diluent with the addition of a suitable base, i.e., a base which protonates the intermediate V, at a temperature within a range from room temperature to the boiling point of the solvent . Compounds of formula VI are known, and some of them can be purchased or they can be prepared in a generally known manner. If R "" in compounds of the general formula la is an ester, the ester group can be dissociated with acid or base or by hydrogenolysis to provide the free carboxylic acids with R1 = COOH. Compound of the type with R1 = COOH can, however, also be obtained directly by deprotonation of intermediate V where R1 = COOH with three equivalents of a suitable base and by reaction with compounds of the general formula VI. Again, the reaction is carried out in an inert solvent at a temperature ranging from room temperature to the boiling point of the solvent. The base that can be used is an alkali metal hydride or alkaline earth metal hydride such as, for example, sodium hydride, potassium hydride or calcium hydride, a carbonate such as, for example, alkali metal carbonate, for example, sodium or potassium carbonate, an alkali metal or alkali metal hydroxide Such as, for example, sodium or potassium hydroxide, an organometallic compound such as, for example, butyl lithium or alkali metal amide, such as, for example, lithium diisopropylamide and lithium amide. The compounds according to the invention of the general formula I wherein R'R'N is sulfone gone which can be obtained from amines of the general formula VII and are prepared according to that described in D? 19726146.9. For this purpose, VII is reacted through generally known methods with sulphuryl halides and, if "is an ester, the ester group is cleaved with acid or base or by hydrogenolysis.

VII Ib Compounds of the formula I can also be prepared starting from the appropriate carboxylic acids, ie, compounds of the formula I wherein R- is COOH, first converting it in conventional manner into an activated form, such as for example acid, anhydride or imidazolyl halide, and then reacting the latter with a suitable hydroxyl compound HOR ° or sulfonamide H2NSO? Rc. This reaction can be carried out in conventional solvents and frequently requires the addition of a base, in which case the bases mentioned above are suitable. These two steps can also be simplified, for example by allowing the carboxylic acid to act in the presence of a dehydrating agent such as a carbodiimide on the hydroxyl compound or the sulfonamide. It is also possible to prepare compounds of the formula I starting from the salts of the appropriate carboxylic acids, ie, from compounds of the formula I, wherein R 1 is a COOM group, wherein M can be a metal cation alkaline or the equivalent of an alkaline earth metal cation. These salts can react with many compounds of formula RD wherein D is a conventional nucleophosphate leaving group such as, for example, halogen such as chlorine, bromine, iodine or arylsulfonyl or alkylsulfonyl optionally substituted by halogen, alkyl or haloalkyl, for example toluenesulfonyl and methylsulfonyl or another equivalent leaving group. Compounds of the formula R-D with a reactive substituent D are known or can be obtained easily with general knowledge of the expert. This reaction can be carried out in conventional solvents and is carried out advantageously in the presence of a base, in which case the bases mentioned above are suitable. Compounds of the formula I wherein R is tetrazolyl can be prepared according to the methods described in WO 96/11914 from the corresponding carboxylic acids (formula I with R1 = COOH). In some cases, it is necessary to employ generally known protecting group techniques to prepare the compounds I in accordance with the present invention. For example, if RR5N = 4-HO-phenyl-CONH-, the hydroxyl group can initially be protected as benzyl ether, which is then dissociated at a suitable stage in the reaction sequence. Compounds of formula I and V can be obtained in enantiomerically pure form by carrying out a resolution of classical racemate with suitable enantiomerically pure bases, as for example those described in WO 96/11914, with racemic or diastereomeric compounds of the formula I and V. In order to achieve the biological effect, preferred carboxylic acid derivatives of the general formula I - both as pure enantiomers or as pure diastereomers and as mixtures thereof - are the derivatives in which the substituents have the following meanings R "is tetrazolyl or a group C-R wherein R has the following meaning: a) a radical 0R wherein R ° is: hydrogen, the cation of an alkali metal, the cation of an alkaline earth metal, a physiologically tolerated organic ammonium ion such as, for example, alkylammonium C: -C_ tertiary or the ammonium ion; C-C-cycloalkyl, C-C-alkyl, phenol CH.sub.1, which may be substituted by one or more of the following radicals: halogen, C: -C4 alkyl, C_-C_haloalkyl, hydroxyl, alkoxy C -.- C4, mercapto, alkyl C-C4, NH (alkyl C.-C), N (alkyl) C.-C4) _; a C3-C3 alkenyl group or an alkynyl group-C-, it being possible for these groups in turn to carry from one to five halogen atoms; R: It can also be a phenyl radical which can carry from one to five halogen atoms and / or from one to three of the following radicals: C_-C4 alkyl / C-C haloalkyl, hydroxyl, alkyloxy C.-C4, mercapto, alkylthio C: -C_, NH (alkyl C.-C: ,, N (alkyl C_- C k, b) a 5-membered heteroaromatic system which is linked through a nitrogen atom, for example pyrazolyl, imidazyl, and triazolyl, which can carry one or two halogen atoms or one or two C- alkyl groups .-C. or one or two C_-C alkoxy groups; c) a group (9)? -O -. { CH 3.) 'p in dor.de k you can take values 0, 1 and 2, p can assume the values 1, 2, 3 and 4, and R is C: -C4 alkyl, CC: cycloalkyl, C ^ - alkenyl, alkynyl Cj -C- or phenyl which may be substituted by one or more, for example one to three of the following radicals: halogen, C2-C4 alkyl, hydroxy, C: -Calkoxy, alkylthio-C, NH (C-alkyl) -C4), N (C-C4 alkyl) :, mercapto; d) a radical I H L O wherein R ° is: Ci-C4 alkyl, C3-C alkenyl, C alqu-C alkynyl, C3-Ce cycloalkyl, it being possible for these radicals to carry a C alco, -C 4 alkoxy, Cilt-C 4 alkylthio radical and / or a phenyl radical according to what is mentioned in c); C1-C4 haloalkyl or phenyl, optionally substituted in particular according to that mentioned in c); W and Z (which may be identical or different): nitrogen or methine; provided that Q = nitrogen if W and Z = methine; X is nitrogen or CR '; And it is nitrogen or CR10; Q is nitrogen or CR? I; provided that X = CR '' and Y = CR "" if Q = is nitrogen; Rx and R (which may be identical or different): phenyl or naphthyl, each of which may be substituted by one or more of the following radicals: halogen, cyano, hydroxyl, mercapto, C1-C4 alkyl, C1-C4 haloalkyl , C2-C4 alkoxy, phenoxy, C2-C4 haloalkoxy, C1-C4 alkylthio, amino, NH (C? -C4 alkyl), N (C: -C4 alkyl) 2 or phenyl, which may be substituted one or more times, for example one to three times by halogen, cyano, Ci-C4 alkyl, C?-C4 haloalkyl, C: -C 4 alkoxy, C2-C haloalkoxy or C2-C4 alkylthio; either phenyl or naphthyl, joined together in ortho positions by link direct, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or a group S0, -? H or N-alkyl; R4 a) a radical wherein R ": is phenyl, naphthyl or a five or six member heteroaromatic system comprising one to three nitrogen atoms and / or a sulfur or oxygen atom, it being possible for diches radicals to be constituted once or several times by halogen, cyano, hydroxyl, mercapto, C_-C4 alkyl, hydroxyalkyl C.-Cj, haloalkyl C: -C, alkoxy C_-C4, haioalkoxy C: -C4, alkylthio C_-C, amino, NH (C: -C alkyl) ), N (C_-C4 alkyl), HNSO :, (C? -C alkyl) NHS02, (C: -C4 alkyl) 2NS02, or phenoxy or phenyl, each ur of which one or more may be substituted times, for example one to three times, by halogen, cyano, C_-C4 alkyl, C_-C4 haloalkyl, C_-C4 alkoxy, C: -C4 haloalkoxy and / or C: -C_alkyl: b) a radical O II - S- R13 II or with R'J is C.sub.4 -C.sub.4 alkyl, C.sub.1 -C.sub.9 O. phenyl haloalkium, it being possible for the phenyl radical itself to carry from one to five halogen atoms and / or from one to three of the following radicals: alkyl C ? -C, haloalkyl C.-C., C2-C4 alkoxy; R "is hydrogen, methyl, R" and R * '(which may be identical or different, are: hydrogen, halogen, C_-C alkoxy, C_-C4 haloalkoxy, C-C4 alkylthio, NH (C_-C4 alkyl) , N (C: -C alkyl) 2, C-C4 alkyl, C-C alkenyl, it being possible for these radicals to be substituted by halogen, hydroxyl, mercapto, cyano, or CR 'or CR1"are linked with CR11 in accordance with that indicated for R "" to provide a 6-membered ring, R "is hydrogen, halogen, C_-C4 alkoxy, C-C4 haloalkoxy, C: -C alkylthio, NH (C_-C_ alkyl) ), N (C-C-alkyl), Cyan, C-C alkyl, C_-C_ alkenyl, it being possible for each of these radicals to be substituted once or twice by: halogen, cyano, C-C4 alkoxy or CR "" forms, together with CR 'or CR ", a 5 or 6 membered alkylene or alkenylene ring which may be substituted by one or two C: -C; alkyl groups, and wherein in each case one or more methylene groups can be replaced by oxygen, sulfur -NH or -N (C-C alkyl). Particularly preferred compounds of the formula I - both as pure pure enantiomers or pure diastereomers and as mixtures thereof - are the compounds in which the substituents have the following meanings: R "is tetrazolyl or a group O ¡i C-R wherein R has the following meaning: a) a radical ORc, wherein R is: hydrogen, the cation of an alkali metal, the cation of an alkaline earth metal or the ammonium ion; alkyl C -.- C., CH.-phenyl, which may be substituted by one or more of the following radicals: halogen, alkyl C-C4, C 1 -C 4 haloalkyl, C 4 -C 4 alkoxy; R 'can also be a phenyl radical which can carry one to five halogen atoms and / or one to three of the following radicals: C_-C4 alkyl, C-C4 haloalkyl, alkoxy C: -C; b) a 5-membered heteroaromatic system linked through a nitrogen atom, such as for example imidazolyl, and triazolyl, which may contain one or two halogen atoms or one or two C.sub.4 -C.sub.4 alkyl groups or one or two C.sub.C.sub.4 alkoxy groups; c) a group -0- (CH_) p s_ R1 in dcr.de k can assume the values 0, 1 and 2, p can assume the values 1, 2, 3 and 4, and R is C alquilo-C alkyl, C3-C- cycloalkyl, or phenyl, which can be substituted by one or several, for example one to three, of the following radicals: halogen, C -.- C4 alkyl, C.-C4 alkoxy; d) a radical OR IJ Rß H II or wherein R "is: C-C alkyl, C3-C: cycloalkyl, it being possible for these radicals to carry a C-C4 alkoxy radical, and / or a phenyl radical in accordance with c); C2-C4 haloalkyl or phenyl, optionally substituted in particular in accordance with c); W and Z (which may be identical or different): nitrogen or methine; provided that Q = nitrogen if W and Z = methine; X is nitrogen or CR ?; And it is nitrogen or CR "'; Q is nitrogen or CR11, provided that X = CR' and Y = CR" if Q = is nitrogen; R- and RJ (which may be identical or different) are: phenyl groups which may be substituted by one or more of the following radicals: halogen, C: -C alkyl, C-C haloalkyl, C: -C_ alkoxy, phenoxy, alkylthio C.-C ,, NH (C-C4 alkyl), N (C: -C4 alkyl): or phenyl, which may be substituted one or more times, for example one to three times by halogen, C_- alkyl C, C 1 -C 4 haloalkyl, C 1 -C alkoxy, or C 1 -C 4 alkylthio; or phenyl groups joined together in ortho positions through a direct bond, a methylene group, ethylene or ethenylene, an oxygen or sulfur atom or an SO: -, NH- or N-alkyl group; R4 a) a radical R «A wherein R ~~ is phenyl or a five or six member heteroaromatic system comprising one to three nitrogen atoms and / or a sulfur or oxygen atom, it being possible for said radicals to be formed once or several times by halogen , hydroxyl, C: -C alkyl, C_-C4 haloalkyl, C: -C4 alkoxy, C_-C4 haloalicyloxy, phenoxy, C-C4 alkylthio, NH (C-C4 alkyl), N (C: -C alkyl) .);, (C-C4 alkyl) NHSO :, (C-C4 alkyl) 2NSO, or phenyl which may be substituted one or more times, for example one to three times, by halogen, C: - alkyl; C, haloalkyl C -.- C, alkoxy C: -C4 and / or haloalkoxy C: -C4; b) an O radical? • -SR "II or wherein R "J is C_-C4 alkyl / C_-C4 haloalkyl or phenyl, it being possible for the phenyl radical in turn to carry one to five halogen atoms and / or one to three of the following radicals: C? -C4 alkyl? , haloalkyl C_-C4, C-C4 alkoxy, RD is hydrogen, methyl, R9 and R "'J (which can be identical or different) are: hydrogen, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, NH (C 1 -C 4 alkyl); C.sub.1 -C.sub.4 alkyl, it being possible for these radicals to be substituted by halogen; or either CR9 or CR10 are linked with CR11 in accordance with that indicated for Ri to form a 5 or 6 member ring; R x ± is hydrogen, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio; C 1 -C 4 alkyl, it being possible for these radicals, in each case, to be replaced one or more times by halogen; or alternatively CRa forms, together with CR9 or CR10, a 5- or 6-membered alkylene or alkenylene ring which may be substituted by one or two C3-C4 alkyl groups, and wherein in each case, one or more methylene groups may be be replaced by oxygen, sulfur -NH or -N (C_-C4 alkyl). The compounds of the present invention offer a novel potential treatment of hypertension, 'pulmonary hypertension, myocardial infarction, chronic heart failure, angina pectoris, acute / chronic renal failure, renal insufficiency, cerebral vasospasm, cerebral ischemia, subarachnoid hemorrhages, migraine, asthma, atherosclerosis, endotoxic shock, endotoxin-induced organ failure , intravascular coagulation, restenosis after angioplasty, benign prostatic hyperplasia, hypertension or renal insufficiency induced by intoxication and ischemia, cyclosporine-induced renal failure, erectile dysfunction, metastasis and growth of mesenchymal tumors, cancer, prostate cancer, renal failure induced by contrast agent, pancreatitis, gastrointestinal ulcers. The invention also relates to combination products which consist of endothelin receptor antagonists of the formula I and inhibitors of the renin-angiotensin system. The inhibitors of the renin-angiotensin system are renin inhibitors, angiotensin II antagonists and, in particular, angiotensin-converting enzyme (ACE) inhibitors. These combination products are especially suitable for the treatment and prevention of hypertension and its sequelae, and for the treatment of heart failure. The good effect of the compounds can be observed through the following tests: Studies of receptor binding CHO cells that express ETA receptor or human ET2 cloned were used for binding studies. Membrane preparation CHO cells expressing ETA or ETB receptors were cultured in DMEM NUT MIX F12 medium (Gibco, No. 21331-020) with 10% fetal calf serum (PAA Laboratories GmbH, Linz, No. A15-022) , 1 mM glutamine (Gibco No. 25030-024), 100 U / ml penicillin and 100 μg / ml streptomycin (Sigma No. P-0781). After 48 hours, the cells were washed with PBS and incubated with PBS containing 0.05% trypsin at a temperature of 37 ° C for 5 minutes. This was followed by neutralization with medium, and the cells were collected by centrifugation at 300 x g. For membrane preparation, the cells were adjusted to a concentration of 10d cells / ml of buffer (50 mM Tris buffer, HCl, pH 7.4) and then disintegrated with ultrasound (Branson 250 sonicator, 40-70 seconds / constant output 20 ). Binding assays For the assay of receptor binding ET_, or ET ?, the membranes were suspended in incubation buffer (50 mM Tris-HCl, pH 7.4 with 5 mM MnCl2, 40 μg / ml bacitracin and 0.2 BSA %) in a concentration of 50 μg of protein per test mixture and said membranes were incubated with 25 pM [125 I] -ET? (ET receptor assay ,,) or 25 pM [125I] -ET3 (assay of ETB receptor) in the presence and absence of test substance at a temperature of 25 ° C. The non-specific binding was determined using 10"7 M ETi After 30 minutes, filtration through fiber filters GF / B glass (Whatman, England) in a Skatron cell harvester (Skatron, Lier, Norway) separated the free radioligand from the bound radioligand, and the filters were washed with Tris-HCl buffer at ice temperature, pH 7.4, with BSA at 0.2%. The radioactivity collected in the filters was quantified using a Packard 2200 CA liquid scintillation counter. ET in vivo antagonist test: SD male rats weighing 25-0-300 g were anesthetized with amobarbital, artificially ventilated, vagotomized and their spinal cord was cut. The carotid artery and the jugular vein were catheterized. In control animals, intravenous administration of 1 mg / kg ET1 results in a remarkable elevation of blood pressure that persists for a long period of time. The test animals received i.v. (1 l / kg) of the test compounds 30 minutes before ET1 administration. To determine ET antagonist properties, changes in blood pressure in the test animals were compared with changes in blood pressure in the control animals. Oral test of ET receptor antagonists: Male normotensive rats (Sprague Dawley, Janvier) weighing 250-350 g are pretreated with the test substances orally. 80 minutes later, the animals are anesthetized with urethane, and the carotid artery (to measure blood pressure) and the jugular vein are catheterized (administration of large endothelin / endothelin 1). After a period of stabilization, it is administered large endothelin (20 μg / kg), volume administered 0.5 ml / kg) or ET1 (0.3 μg / kg), volume administered 0.5 ml / kg) intravenously. Blood pressure and heart rate are recorded continuously for 30 minutes. Notable and lasting changes in blood pressure are calculated as the area under the curve (ABC). To determine the antagonistic effect of the test substances, the area under the curve for the animals treated with substance is compared to the area under the curve for the control animals. The novel compounds can be administered orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally) in a conventional manner. The administration can also be carried out with vapors or sprays through the nasopharyngeal space. The dosage depends on the age, condition and weight of the patient and the mode of administration. In general terms, the daily dose of active ingredient is approximately 0.5 to 50 mg / kg of body weight in the case of oral administration and of approximately 0.1 to 10 mg / kg of body weight in the case of parenteral administration. The novel compounds can be administered in conventional solid or liquid dosage forms, for example, as uncoated or film coated tablets, capsules, powders, granules, suppositories, solutions, ointments, creams or sprays. They are produced in a conventional. The active ingredients can, for this purpose, be processed with conventional pharmaceutical auxiliaries such as binders for tablets, bulk agents, preservatives, tablet disintegrating agents, flow regulators, plasticizers, wetting agents, dispersing agents, emulsifiers, solvents. , slow release agents, antioxidants and / or blowing gases (C. Sucker et al .: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1991). The administration forms obtained in this manner usually contain from 0.1 to 90% by weight of active ingredient. Synthesis Examples Example 1: Methyl 3-amino-2-hydroxy-3-diphenyl-propionate 0.2 g of a 10% palladium / carbon hydrogenation catalyst was added to a solution of 3-azido-2-hydroxy-3, Methyl 3-diphenylpropionate (5.71 g, 19.2 mmol) in methanol (100 mL). The mixture was stirred under an atmosphere of hydrogen at room temperature for 48 hours. The catalyst was then removed by filtration and the solvent was removed by distillation. The residue was taken up in 5% aqueous citric acid and the resulting solution was extracted with ether. The aqueous phase was then turned alkaline with a dilute solution of sodium hydroxide and again extracted with ether. The extracts obtained from the The alkaline phase was dried in magnesium sulfate, and the solvent was removed in vacuo. 4.03 g (14.9 mmol, 77% yield) of the pure amine were obtained. 1 H-NMR (200 MHz): 7.5 (m, 2H); 7.2-7.4 (m, 8H), 5.0 (s, 1H); 4.2 (s br, 1H), 3.4 (s, 3H); 2.0-2.4 (s br, 2H). Example 2: 2- (4-methoxybenzoylamino) -1-methoxycarbonyl-2, 2-diphenylethyl pyridine 4-methoxybenzoate (1.17 g, 14.7 mmol), a spatula tip of dimethylaminopyridine, and para-methoxybenzoyl chloride 2.52 g, 14.7 mmol) were added successively to a solution of methyl 3-amino-2-hydroxy-3, 3-diphenyl propionate (2. OD g, 7. 37 mmcl) in dichlorometre.o (10 ml). The mixture was stirred at room temperature for 4 hours and then, for treatment, mixed with water and extracted with ether. The combined organic phases were washed with aqueous citric acid and saturated brine and then dried over magnesium sulfate.

The solvent was removed by evaporation in vacuo to provide the crude bisacylation product, which was used without further purification (1.37 g; 28% with a purity of 82% in accordance with HPLC). Example 3: Methyl 2-hydroxy-3- (4-methoxybenzoylamino) -3,3-diphenylpropionate 4-methoxybenzoate 2- (4-methoxybenzoylamino) -1- methoxycarbonyl-2, 2-diphenylethyl (1.37 g, 2.08 mmol with a purity of 82%) was dissolved in methanol (20 mL), and potassium carbonate (863 mg, 6.25 mmol) was added. The resulting mixture was stirred at room temperature for 16 hours and the solvent was removed in vacuo. The residue was taken up with water and extracted with ether; a colorless solid was precipitated during this and was isolated by filtration and said solid was identical to the title compound. The aqueous phase was then extracted again with ethyl acetate. The organic phases were combined and dried over magnesium sulfate, and the solvent was removed in vacuo. The crude product was purified by crystallization from dichloromethane / ether / n-hexane, resulting in a colorless solid (503 mg, 60% yield). Example 4: benzyl 2-hydroxy-3- (4-methoxybenzoylamino) -3,3-diphenylpropionate 2.11 ml of a 1 molar sodium hydroxide solution were added to a solution of 2-hydroxy-3- (4-methoxybenzoylamino) -3, 3-methyl diphenylpropionate (503 mg, 1.24 mmol) in 1: 2 water / tetrahydrofuran (50 mL) and stirred at room temperature for 60 hours. The initial material had been substantially converted after this: to complete the reaction, a 1 molar solution of sodium hydroxide (2.11 ml), and stirring, were added again.

He continued for 1 hour. The mixture was diluted with water, extracted with ether, acidified with citric acid and extracted again with ether. The extracts obtained from the acid phase were dried in magnesium sulfate and the solvent was removed in vacuo. The residue (406 mg) was taken up in dimethylformamide (20 ml), and potassium carbonate (179 mg, 1.30 mmol) and benzyl bromide (195 mg, 1.14 mmol) were successively added. The resulting mixture was stirred at room temperature for 20 hours and then 5% aqueous citric acid was added. After dilution with water, the extraction was carried out with dichloromethane and then with ether (the product is only moderately soluble in ether). The organic extracts were washed completely with water and then with saturated brine and dried over magnesium sulfate, and the solvent was removed in vacuo. Traces of benzyl bromide and dimethylformamide were removed by washing the residue with a little ether / n-hexane 1: 1. 487 mg (79%) of the pure benzyl ester was obtained. Example 5: 2- (4,6-diethyl [1,3,5] triazin-2-yloxy) -3- (4-methoxy-benzoylamino) -3,3-diphenyl-propionate benzyl Potassium carbonate (80 g. mg, 0.58 mmol) and 2-chloro-4,6-diethyl- [1, 3, 5] triazine (74 mg, 0.43 mmol) to a solution of 2-hydroxy-3- (4-methoxybenzoylamino) -3, 3 -benzyl diphenylpropionate (139 mg, 0.29 mmol.) in dimethylformamide (15 ml). The mixture was heated to a temperature of 60 ° C and stirred this temperature for 4 hours. The reaction was stopped by the addition of 5% citric acid (10 ml). Dilution with water was followed by extraction with ether, and the combined organic phases were washed with saturated brine and dried over magnesium sulfate. The solvent was removed by distillation; the residue was purified by flash chromatography (eluent: ethyl acetate in cyclohexane 30-50%). 124 mg of the objective compound was obtained with a purity of 90% (according to HPLC) (yield: 63%). Example 6: 2- (4,6-Diethyl [1,3,5] tnazin-2-yloxy) -3- (4-methoxybenzoylamino) -3,3-diphenylpropionic acid < 1-4) A 10% palladium / carbon hydrogenation catalyst was added (spatula tip) to a solution of benzyl 2- (4,6-diethyl- [1, 3, 5] triazin-2-yloxy) -3- (4-methoxybenzoylamino) -3,3-diphenylpropionate (124 mg 0.18 mmol) cor. a purity of 90%) in ethyl acetate (15 ml) and stirred under a hydrogen atmosphere at room temperature for 3 hours. The catalyst was then removed by filtration and the solvent was removed by vacuum distillation. The residue was crystallized from dichloromethane / ether / n-hexane, which resulted in 99 mg (yield: 73%) of the pure carboxylic acid. 1 H-NMR (200 MHz): 7.8 (m, 3H); 7.6 (dd, 2H); 7.1-7.4 (m, 4H); 6. 9 (d, 2H); 6.6 (s, 1H); 3.8 (s, 3H); 2.7 (q, 4H); 1.2 (t, 6H). ESI-MS: M = 526. The following products were synthesized analogously: 2- (4,6-Diethyl [1,3,5-triazin-2-yloxy) -3- (3,5-dimethoxybenzoylamino) -3 acid , 3-diphenylpropionic (1-327) 1 H-NMR (200 MHz): 7.9 (s, 1H); 7.6. 2H); 7.2-7.5 (m, 8H); 6. 9 (d, 2H); 6.7 (s, 1H); 6.6 (t, 1H); 3.8 (s, 6H); 2.7 (q, 4H); 1.2 (t, 6H). ESI-MS: M * = 556. 3- (3,5-Dimethoxybenzoyl) laminc -2- (4,6-dimethyl-2-pyrimidinyloxy) -3,3-diphenylpropionic acid (1-245) 1H-NMR (200 MHz): 8.1 (s, br, 1H); 7.7; m, 2H); 7.2-7.5 (m, 8H); 7.0 (d, 2H); 6.70 (s, 1H); 6.65 (s, 1H); 6.60 (t, 1H); 3. 8 (s, 6H), 2.3 (s, 6H). ESI-MS: Mt = 527. 3-Benzoylamino-2- (4,6-dimethyl-2-pyrimidinyloxy) -3,3-diphenylpropionic acid (1-66) 1 H-NMR (200 MHz): 8.2 (s, br , 1 HOUR); ^ .8 (, 2H); 7.6 (m, 2H); 7. 1-7.5 (m, 11H); 6.7C (s, 1H); 6.65 (s, 1H); 2.3 (s, 6H).

ESI-MS: Mt = 467. 2- (4,6-Dimethyl-2-pyrimidinyloxy) -3- (4-methylbenzoylamino) -3,3-diphenylpropicnic acid (1-199) 1 H-NMR (200 MHz): 8.3 (s, br, 1H); 7.7 id, 2H); 7.6 (m, 2H); 7. 1-7.5 (m, 10H); 6.7 (s, 2H); 2.4 (s, 3H); 2.3 (s, 6H). ESI-MS: W = 481. EXAMPLE 7: 2-methyl-4,4-diphenyl-4,5-dihydrooxazole-5-carboxylic acid benzyl ester Boron trifluoride etherate d.04 g; 56.7 mmol) was added to a solution of 3,3-diphenyloxyradio-2-carboxylic acid benzyl ester (10.0 g, 28.3 mmol) in acetonitrile (100 mL). The mixture was stirred at room temperature for 1 hour and then concentrated in a rotary evaporator. The residue was taken up in water, saturated with sodium chloride and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate, and the solvent was removed in vacuo. The residue (13.5 g) was further employed without purification. Example 8: benzyl 3-amino-2-hydroxy-3-diphenyl-propionate 2-methyl-4,4-diphenyl-4,5-dihydrooxazole-5-carboxylic acid benzyl ester (13.5 g, crude) was stirred in a mixture of methanol (25 ml), water (50 ml) and concentrated hydrochloric acid (50 ml) at room temperature for 60 hours. The solution was then decanted from the undissolved material; the residue was stirred in the aforementioned mixture again for 3 hours. The decantation was repeated, the remaining residue was discarded. The two liquid phases were combined and adjusted to a pH of 8-9 with sodium hydroxide solution, so a crystallization started. The crystals were washed with ether and removed by filtration with suction: 4.65 g of the required aminoalcohol were obtained with a purity of 97%. 1 H-NMR (200 MHz): 7.4 (m, 2H); 7.1-7.3 (m, 11H); 7.0 (m, 2H); 5.0 (s, 1H); 4.9 (d, 1H); 4.7 (d, 1H); 1.9-2.5 (s, br, 2H) example 9: benzyl 2-hydroxy-3, 3-diphenyl-3- (4-trifluoromethylbenzoylamino) -propionate Pyridine (94 mg, 1.00 mmol), a spatula tip were successively added of dimethylaminopyridine, and para-trifluoromethylbenzoyl chloride (215 mg, 1.00 mmol) to a solution of benzyl 3-amino-2-hydroxy-3, 3-diphenyl propionate (365 mg, 1.00 mmol) in dichloromethane (50 mL). The mixture was stirred at room temperature for 60 hours and then treated by extraction with dilute citric acid. The organic phase was dried over magnesium sulfate and the solvent was removed in vacuo. The residue (540 mg) was taken up in chloroform (50 ml) and, after addition of pyridine (36 mg, 0.45 mmol) and some dimethylaminopyridine crystals, refluxed for 4 hours. After cooling, the treatment was carried out by extraction with dilute citric acid. The organic phase was dried over magnesium sulfate, and the solvent was removed in vacuo. The residue was crystallized at from ether / n-hexane; 235 mg (45% yield) of the pure product were obtained. 1 H-NMR (200 MHz): 7.7 (d, 2H); 7.5 (d, 2H); 7.2-7.4 (m, 13H); 7.1 (d, 2H); 5.5 (d br, 1H); 5.0 (m, 2H); 4.6-4.8 (s br, 1H). EXAMPLE 10 Benzyl 2- (4,6-dimethyl-2-pyrimidinyloxy) -3,3-diphenyl-3- (4-trifluoromethylbenzoylamino) propionate Potassium carbonate (100 mg, 0.72 mmol) and 2-methylsulfonyl- were successively added. 4,6-dimethylpyrimidine (96 mg, 0.51 mmol) was added to a solution of benzyl 2-hydroxy-3, 3-diphenyl-3- (4-trifluoromethylbenzoylamino) propionate (220 mg, 0.42 mmol) in dimethylformamide (15 mL). The mixture was heated to a temperature of 80 ° C and stirred at this temperature for one hour. The reaction was suspended by the addition of dilute citric acid and water (200 ml). After extraction with ether, the organic phase was dried over magnesium sulfate and concentrated in vacuo. The residue was crystallized from ether / n-hexane; 158 mg (60%) of the pure title compound were obtained. Example 11: 2- (4,6-Dimethyl-2-pyrimidinyloxy) -3,3-diphenyl-3- (4-trifluoromethylbenzoylamino) propionic acid (1-201) A 10% paladic hydrogenation catalyst / carbon (spatula tip ) was added to a solution of 2- (4,6-dimethyl-2-pyrimidinyloxy) -3,3-diphenyl-3- (4-trifluoromethylbenzoylamino) Benzyl propionate (150 mg, 0.24 mmol) in ethyl acetate (50 ml), and the mixture was stirred under a nitrogen atmosphere at room temperature for 2 hours. The catalyst was then removed by filtration and the solvent was distilled in vacuo. The residue was crystallized from ether / n-hexane, yielding 100 mg (78%) of the pure carboxylic acid. 1 H-NMR (200 MHz): 8.3 (s br, 1 H); 7.9 (d, 2H); 7.7 (m, 4H); 7. 1-7.4 (m, 8H); 6.7 (s, 1H); 6.6 (s, 1H); 2.3 (s, 6H). ESI-MS: M "= 535. The following products were prepared analogously: 3- (3,4-Dimethoxybenzoylamino) -2- (4,6-dimethyl-2-pyrimidinyloxy) -3,3-α-phenylpropionic acid (1-48) 1 H-NMR (200 MHz): 8.2 (br, 1 HOUR); 7.7 (m, 2H); 7.1-7.5 (m, 10H); 6.8 (d, 1H); 6.7 (s, 1H); 6.6 (s, 1H); 3.9 (s, 3K; 3.8 (s, 3H); 2.3 (s, 6H). ESI-MS: M "= 527. 3- (3, -difluorobenzoylamino) -2- (4,6-dimethyl-2-pyrimidinyloxy) -3,3-diphenylpropionic acid (1-340) 1H-NMR (200 MHz): 8.2 (s br, 1H); 7.5-7.8 (m, 5H); ".1-7.4 (m, 8H); 6.7 (s, 1H); 6.6 (s, 1H); 2.3 (s, 6H). ESI-MS: Mt = 503. 2- (4,6-Dimethyl-2-pyrimidinyloxy) -3- (4-fluorobenzoylamino) -3,3-diphenylpropionic acid (1-170) 1 H-NMR (200 MHz): 8.2 (s br, IH); 7.8 (dd, 2H); 7.6 (, 2H); 7. 0-7.5 (m, 10H); 6.7 (s, 1H); 6.6 (s, 1H); 2.3 (s, 6H). ESI-MS: M "= 485. Example 12: Methyl 2- (4,6-dimethoxy-2-pyrimidinyloxy) -3-methanesulfonylamino-3-diphenyl-propionate Methanesulfonyl chloride (83 mg, 0.73 mmol) was added, pyridine (82 mg, 1.04 mmol) and dimethylaminopyridine (spatula tip) to a solution of methyl 3-amino-2- (4,6-dimethoxy-2-pyrimidinyloxy) -3,3-diphenylpropionate (213 mg, 0.52 mmol ) in dichloromethane (15 ml) The mixture was stirred at room temperature for one week, since the conversion was incomplete, an equivalent of 0.20 mol of additional methanesulfonyl chloride was added, and the stirring was carried out again at room temperature during 3 days.For the treatment, the mixture was diluted with ether and washed successively with dilute citric acid, sodium bicarbonate solution and saturated brine.The organic phase was dried in magnesium sulfate, and the solvent was removed in vacuo. of citric acid was neutralized and extracted with ether, the organic phases obtained from there were dried and evaporated in accordance with what was described above. The residue (206 mg) was additionally employed without further treatment. Example 13: 2- (4,6-Dimethoxy-2-pyrimidinyloxy) -3-methanesulfonylamino- acid 3, 3-diphenylpropionic (1-156) 0.50 ml of a 1 molar sodium hydroxide solution was added to a solution of 2- (4,6-dimethoxy-2-pyrimidinyloxy) -3-methanesulfonylamido-3, 3-diphenylpropionate of methyl (181 mg, crude) in 1: 2 water / tetrahydrofuran (30 ml), and the mixture was stirred at room temperature for 5 days. To complete the reaction, an additional 0.5 molar equivalent of a 1 molar sodium hydroxide solution was added, and the mixture was stirred again for 24 hours. After dilution with water and extraction with ether, the aqueous phase was acidified with citric acid and extracted again with ether. The extracts obtained from the acid phase were dried in magnesium sulfate, and the solvent was removed in vacuo. Crystallization of the residue from diclcromethane / n-hexane gave the pure objective compound (71 mg, 33% yield in two steps). 1 H-NMR (200 MHz): 7.6-7.7 (m, 2H); 7.3-7.5 (m, 8H); 6.5 (s, 1H); 6.3 (br, 1H); 5.8 (s, 1H); 3.9 (s, 6H); 2.2 (s, 3Hi ESI-MS: M "= 473. The compounds that appear in the list in Table 1 can be prepared analogously or in accordance with what is described in the general part.

Table I No. R1 R2, R3 R4RDN 1-1 COOH Phenyl 4-OMe-phenyl-CONH 1-2 COOH Phenyl 5-F-3-pyridyl-CONH 1-3 COOH Phenyl 2-thiazolyl-CONH 1-4 COOH Phenyl 4-OMe-phenyl-CONH 1-5 COOH Phenyl 4-OMe-phenyl-CONH 1-6 COOH Phenyl 4-OMe-phenyl-CONH 1-7 COOH Phenyl 3, 4-Di-F-phenyl-CONH 1-8 COOH Phenyl 3, 5-Di-F-phenyl-CONH 1-9 COOH 4-F-Phenyl 4-OMe-phenyl-CONH 1-10 COOH Phenyl 2-thiazolyl-CONH 1-11 COOH Phenyl 4-thiazolyl-CONH 1-12 COOH 4-F-Phenyl 4-OMe-phenyl-CONH 1-13 COOH 4-F-Phenyl 4-OMe-phenyl-CONH 1-14 COOH 4-F-Phenyl 4-OMe-phenyl-CONH 1-15 COOH Phenyl 3, 4-Di-F-phenyl-CONH 1-16 COOH Phenyl 3, 5-Di-F-phenyl-CONH 1-17 COOH Phenyl 4-OMe-phenyl-CONMe 1-18 COOH Phenyl 4-thiazolyl-CONH 1-19 COOH Phenyl 4-thiazolyl-CONH 1-20 COOH Phenyl 4-OMe-phenyl-CONMe 1-21 COONa Phenyl 4-OMe-phenyl-CONMe 1-22 COOH Phenyl 4-OMe-phenyl-CONMe 1-23 COOH Phenyl 3, 5-Di-F-phenyl-CONH 1-24 COOH Phenyl 3, 4-Di-F-phenyl-CONH 1-25 COOH Phenyl 4-OMe-phenyl-CONMe 1-26 COOH Phenyl 4-OMe-phenyl-CONMe 1-27 COOH Phenyl 5-Me-2-thiazolyl-CONH 1-28 COOH Phenyl 4-Cl-2-thiazolyl-CONH 1-29 COOH Phenyl 4-OMe-phenyl-CONMe 1-30 COOH Phenyl 4-OMe-phenyl-CONMe 1-31 COOH Phenyl 3, 4-Di-F-phenyl-CONH 1-32 COOH 4-OMe-Phenol 3, 4-Di-F-phenyl-CONH 1-33 COOH Phenyl 4-OMe-phenyl-CONMe 1-34 COOH Phenyl 4-OMe-phenyl-CONMe 1-35 COOH Phenyl 5-CN-2-thiazolyl-CONH 1-36 COOH Phenyl 5-CN-2-pyrrolyl-CONH 1-37 COOH Phenyl 4-OMe-phenyl-CONMe 1-38 COOH Phenyl 4-OMe-phenyl-CONMe 1-39 COOH 4-Me-Phenyl 3, 4-Di-F-phenyl-CONH 1-40 COOH Phenyl 3, 4-Di-F-phenyl-CONH 1-41 COOH 4-F-Phenyl 4-OMe-phenyl-CONMe 1-42 COOH 2-Cl-Phenyl 4-OMe-phenyl-CONMe 1-43 COOH Phenyl 5-CN-2-pyrrolyl-CONH 1-44 COOH Phenyl 2-pyrrolyl-CONH 1-45 COOH Phenyl 4-SMe-phenyl-CONH 1-46 COOH Phenyl 4-SMe-phenyl-CONH 1-47 COOH Phenyl 3, 4-Di-OMe-phenyl-CONH I-4S COOH Phenyl 3, 4-Di-OMe-phenyl-CONH 1-49 COOH Phenyl 4-SMe-phenyl-CONH 1-50 COONa Phenyl 4-SMe-phenyl-CONH 1-51 COOH Phenyl 2-pyrrolyl-CONH 1-52 COOH Phenyl 2-Me-2-pyrrolyl-CONH 1-53 COOH Phenyl 4-SMe-phenyl-CONH 1-54 COOH 4-Cl-Phenyl 4-SMe-phenyl-CONH 1-55 COOH Phenyl 3,4-Di-OMe-phenyl-CONH 1-56 .COOH Phenyl 3, 4-Di-OMe-phenyl-CONH 1-57 COOH Phenyl 4-SMe-phenyl-CONMe 1-58 COOH Phenyl Phenyl-CONH 1-59 COOH Phenyl 2-Naphthyl-CONH 1-60 COOH Phenyl 2-Naphthyl-CONH 1-61 COOH 4-F-Phenyl Phenyl-CONH 1-62 COOH 4-F-Phenyl Phenyl -CONH 1-63 COOH Phenyl 3, 4-Di-OMe-phenyl-CONH 1-64 COOH Phenyl 3, 4-Di-OMe-phenyl-CONH 1-65 COOH Phenyl Phenyl-CONH 1-66 COOH Phenyl phenyl-CONH 1-67 COOH Phenyl 2-naphthyl-CONH 1-68 COOH Phenyl 2-naphthyl-CONH 1-69 COOH Phenyl-CONH 1-70. COO-Ben- Phenyl Phenyl-CONH Cyl 1-71 COOH Phenyl 3-4-Di-OMe-phenyl-CONMe 1-72 COOH Phenyl 3, 4-Di-OMe-phenyl-CONMe 1-73 COOH Phenyl Phenyl-CONH 1-74 COOMe Phenyl Phenyl-CONH 1-75 COOH Phenyl 2-Naphthyl-CONH 1-76 COOH Phenyl 5-OMe-2-Naphthyl-CONH 1-77 COOH Phenyl Phenyl-CONH 1-78 COOH Phenyl Phenyl-CONH 1-79 COOH 4-F-Phenyl 3, 4-Di-OMe-phenyl-CONH 1-80 COOH Phenyl 3, 4-Di-OMe-phenyl-CONH 1-81 COOH Phenyl, phenyl-CONH 1-82 COOH Phenyl, fem l-CCNK 1-83 COOH Phenyl, 5-Cl-Naphthyl-CONH 1-84 COOH Phenyl 6-OMe-2-Naphthi I-CONH 1-85 COOH Phenyl 4-OH-phenyl-CONH 1-86 COOH 4-Me-Phenyl 4-OH-phenyl-CONH 1-87 COOH 2-Cl-Phenyl 3, 4-Di-OMe-phenyl-CONH 1-88 COOH Phenyl 3, 4-Di-CCF.-phenyl-CONH 1-89 COOH Phenyl 4-OH-phenyl-CONMe 1-90 COOH Phenyl 4-OH-phenyl-CONH 1-91 COOH Phenyl 4-Naphthyl-CONH 1-92 COOH Phenyl 4-Naphthyl-CONH 1-93 COOH Phenyl 3-OH-phenyl-CONH 1-94 COOH Phenyl 4 -OH-phenyl-CONH 1-95 COOH Phenyl 3-4-Di-OCF ^ -phenyl-CONH 1-96 COOH Phenyl 3, 4-Di-OCF3-phenyl-CONH 1-97 COOH Phenyl 4-OH-phenyl-CONH 1-98 COOH Phenyl 4-OH-phenyl-CONH 1-99 COOH Phenyl 1-Naphthyl-CONH 1-100 COOH Phenyl 1-Naphthyl-CONH 1-101 COOH 4-F-Phenyl 4-OH-phenyl-CONH 1- 102 COOH Phenyl 4-OH-phenyl-CONMe 1-103 COOH Phenyl 3, 4-Di-OCF-phenyl-CONH 1-104 COOH Phenyl 3, 4-Di-OCF3-phenyl-CONH 1-105 COOEt Phenyl 4-Br-phenyl-CONH 1-106 COOH Phenyl 4-Br-phenyl-CONH 1-107 COOH Phenyl 1-Naphthyl-CONH 1-108 COOH Phenyl 4-Br-2-Naphthyl-CONH 1-109 COOH Phenyl 4-Br-phenyl-CONH 1-110 COOH Phenyl 4-Br-phen? I-CONH 1-111 COOH Phenyl 3,4-Di-OCF; -phenyl-CONH 1-112 COOH Phenyl "3, 4-Di-OH-phenyl-CONH 1-113 COOH 4-Me-Phenyl 4-Br-phenyl-CONH 1-114 COOH Phenyl 4-Br-phenyl-CONH 1-115 COOH Phenyl 5-CN-2-Naphthyl-CONH 1-116 COOH Phenyl 5-OH-2-Naphthyl-CONH 1-117 COOH Phenyl 3-Br-phenyl-CONH 1-118 COOH Phenyl 3-Br-phenyl-CONH 1-119 COOH Phenyl 3,4-Di-OH-phenyl-CONH 1-120 COOH 3-F-Phenyl 3, 4-Di-OH-phenyl-CONH 1-121 COOH Phenyl 3-Br-fenii-CONH 1-122 COOH Phenyl 3-Br-phenyl-CONH I - 123 COOH Phenyl 3-CN-l-Naphthyl-CONH I - 124 COOH Phenyl 3-Cl-l-Naphthyl-CONH I-125 COOH Phenyl 3-Br-phenyl-CONH I-126 COOH 4-Me-Phenyl 3-Br-phenyl-CONH I-127 COOH Phenyl 3-OH-4-OMe-phenyl-CONH I - 128 COOH Phenyl 3-OH-4-OMe-phenyl-CONH I - 129 COOH Phenyl 3-OMe-phenyl-CONH I - 130 COOH Phenyl 4-OMe-phenyl-CONH I - 131 COOH Phenyl 4-OMe-l-Naphthyl-CONH I - 132 COOH Phenyl 2-Imidazolyl-CONH I - 133 COOH Phenyl 4-OMe-phenyl-CONH I - 134 COOH Phenyl 4-OMe-phenyl-CONH I - 135 COOH Phenyl 4-OH-4-OMe-phenyl-CONH I - 136 COOH Phenyl 3-OMe-4-OH-phenyl-CONH I - 137 COOH Phenyl 3-OMe-phenyl-CONH I - 138 COOH 4-F-Phenyl 3-OMe-phenyl-CONH I - 139 COOH Phenyl 2-Imidazolyl-CONH I - 140 COOH Phenyl 2-Imidazolyl-CONH I - 141 COOH Phenyl 3-OMe-phenyl-CONMe I - 142 COOH Phenyl 3-OMe-phenyl-CONMe I - 143 COOH Phenyl 3-OMe-4-OH-phenyl-CONH I - 144 COOH Phenyl 3-F-4-OMe-phenyl-CONH I - 145 COOH Phenyl 4-Cl-phenyl-CONH I - 146 COOH Phenyl 4-Cl-phenyl-CONH I - 147 COOH Phenyl MeSO-NH -148 COOH Phenyl MeS02NH 1-149 COOH Phenyl 4-Cl-phenyl-CONH 1-150 COOH Phenyl 4-Cl-phenyl-CONH 1-151 COOH Phenium 3-F-4-OMe-phenyl-CONH 1-152 COOH Phenyl 3-Cl-4-OMe-phenyl-CONH 1-153 COOH 4-Me-Phenyl 4-Cl-phenyl-CONH 1-154 COOH Phenyl 4-Cl-phenyl-CONH 1-155 COOH Phenyl MeS02NH 1-156 COOH Phenyl MeS02NH 1-157 COOH Phenyl 3-Cl-phenyl -CONH 1-158 COOH Phenyl 3-Cl-phenyl-CONH 1-159 COOH Phenium 3-OMe-4-F-phenyl-CONH 1-160 COOH Phenyl 3-OMe-4-F-phenyl-CONH 1-161 COOH Phenyl 3-Cl-phenyl-CONH 1-162 COOH Phenyl 3-Cl-phenyl-CONH 1-163 COOH Phenyl MeS02NH 1-164 COOH Phenyl MeSO: NH 1-165 COOH Phenyl 3-Cl-phenyl-CONH 1-166 COOH 4-Me-Phenyl 3-Cl-phenyl-CONH 1-167 COOH 3-Me-Phenyl 3-OMe-4-F-phenyl-CONH 1-168 COOH Phenyl 3-CN-4-OMe-phenyl-CONH 1-169 COOH Phenyl 4-F-phenyl-CONH 1-170 COOH Phenyl 4-F-phenyl-CONH 1-171 COOH 4-F-Phenyl MeSO: NH 1-172 COOH Phenyl MeSO-NH -173 COOH Phenyl 4-F-phenyl-CONH 1-174 COOH Phenyl 4-F-phenyl-CONH 1-175 COOH Phenyl 3-CN-4-OMe-phenyl-CONH 1-176 COOH Phenyl 3-OMe-4-CN-phenyl-CONH 1-177 COOH 4-Me-Phenyl 4-F-phenyl-CONH 1-178 COOH Phenyl 4-F-phenyl-CONH 1-179 COOH Phenyl MeSO: NH 1-180 COOH 4-ethyl-Phenyl MeS02NH 1-181 COOH Phenyl 3-F-phenyl-CONH 1-182 COOH Phenyl 3-F-phenyl-CONH 1-183 COOH Phenyl 3-Me-4-OMe-phenyl-CONH 1-184 COOH Phenyl 3-Me-4-OMe-phenyl-CONH 1-185 COOH Phenyl 3-F-phenyl-CONH 1-186 COOH Phenyl 3-F-phenyl-CONH 1-187 COOH Phenyl Phenyl-S02NH 1-188 COOH 4-F-Phenyl phenyl-SO: NH 1-189 COOH Phenyl 3-F-phenyl-CONH 1-190 COOH 4-Me-Phenyl 3-F-phenyl-CONH 1-191 COOH Phenyl phenyl-SONH 1-192 COOH Phenyl 4-CF.O-phenyl-CONH 1-193 COOH Phenyl 3-Me-4-OMe-phenyl-CONH 1-194 COOH Phenyl 3-OMe-4-Me-phenyl-CONH 1-195 COOH Phenyl 4-CF30-phenyl-CONH 1-196 COOH Phenyl 4-CF; 0-phenyl-CONH 1-197 COOH Phenyl phenyl-SO-NH I - 198 COOH Phenyl 4-CF3O-phenyl-CONH I - 199 COOH Phenyl 4-Me-phenyl-CONH I - 200 COOH 4-Me-Phenyl 4-Me-phenyl-CONH I - 201 COOH Phenyl 4-CF3-phenyl-CONH I - 202 COOH Phenyl 4-CF3-phenyl-CONH I - 203 COOH Phenyl phenyl-SO: NH I - 204 COOH Phenyl phenyl-S02NH I - 205 COOH Phenyl 4-CF30-phenyl-CONH I - 206 COOH Phenyl 4-CF3-phenyl-CONH I - 207 COOH Phenyl 4 -Me-fenii-CONMe I - 208 COOH Phenyl 4 -Me-phenyl-CONH I - 209 COOH Phenyl 4-CF-.0-phenyl-CONH I - 210 COOH Phenyl 4 -CF, 0-phenyl-CONH I - 211 COOH Phenyl phenyl-SO; NH I-212 COOH Phenyl phenyl SO NH I-213 COOH Phenyl 4 -CF30- phenyl-CONH I - 214 COOH 4-Me-Phenyl 4-CF-0-phenyl-CONH I - 215 • COOH Phenyl 3-Me-phenyl-CONH I - 216 COOH Phenyl 4-Me-phenyl-CONH I - 217 COOH Phenyl 4-CF.O-phenyl-CONMe I - 218 COOH Phenyl 4-CF; .0-phenyl-CONtMe I - 219 COOH Phenyl phenyl-S02NH I - 220 COOH Phenyl 4-Me-phenyl-S02NH I - 221 COOH Phenyl 4-CF .O-phenyl-CONMe I - 222 COOH Phenyl 4-CF30-phenyl-C0NMe 1-223 COOH Phenyl 4-Me-phenyl-CONH 1-224 COOH Phenyl 4-Me-phenyl-CONH 1-225 COOH Phenyl 3-CF30-phenyl-CONH 1-226 COOH Phenyl 3-CF30-phenyl-CONH 1-227 COOH Phenyl 4-Me-phenyl-SO.NH 1-228 COOH Phenyl 4-Me-phenyl-S03NH 1-229 COOH Phenyl 3-CF30-phenyl-CONH 1-230 COOH Phenyl 3-CF30-pheni l-CONH 1-231 COOH 4-F-Phenyl 4-Me-phenyl-CONH 1-232 COOH Phenyl 4-Me-phenyl-CONMe 1-233 COOH Phenyl 4-CN-phenyl-CONH 1-234 COOH Phenyl 4-CN-phenyl -CONH 1-235 COOH Phenyl 4-Me-phenyl-S02NH 1-236 COOH Phenyl 4-Me-phenyl-S02NH 1-237 COOH Phenyl 4-CN-phenyl-CONH 1-238 COOH Phenyl 4-CN-phenyI-CONH 1-239 COOH Phenyl 3-Cl-4-Me_N-phenyl-CON: -: 1-240 COOH Phenyl 3-Cl-4-Me: N-phenyl-CONH 1-241 COOH Phenyl 4-CN-phenyl-CONH 1-242 COOH Phenyl 4-CF ^ O-phenyl-CONH 1-243 COOH Phenyl 4-Me-phenyl-S02NH 1-244 COOH Phenyl 3-Cl-phenyl-S02NH 1-245 COOH Phenyl 4-CN-phenyl-CONH 1-246 COOH Phenyl 4 -CH3CO-phenyl-CONH 1-247 COOH Phenyl 3, 5-Di-OMe-pheni l-CON e 1-248 COOH Phenyl 3, 5-Di-OMe-phenyl-CONH 1-249 COOMe Phenyl 4-CF.O-phenyl-CONH 1-250 COOH Phenyl 4-CH.CO-phenyl-CONH 1-251 COOH Phenyl 3-Cl-phenyl-S02NH 1-252 COOH Phenyl 3-CI-phenyl-SO: NH 1-253 COOH Phenyl 4-CK.CO-phenyl-CONH 1-254 COOH Phenyl 4-CK.CO-phenyl-CONH 1-255 COOH Phenyl 3, 5-Di-OMe-phenyl-CONH 1-256 COOH 3-Me-Phenyl 3, 5-Di-O e-phenyl-CONH 1-257 COOH Phenyl 4-Et0-fer_il-CONH 1-258 COOH Phenyl 4-EtO-fer.il-CONH 1-259 COOH Phenyl 4-Cl-phen I-S0NH 1-260 COOH Phenyl 4-Cl-fer. l-S02NH 1-261 COOH Feniio 3-EtC-phenyl-CONH 1-262 COOH Phenyl 4-EtO-phenyl-CONH 1-263 COOH Phenyl 4-Pyridyl-CONH 1-264 COOH Phenyl 4-Pyridyl-CONH 1-265 COOH 4-F-Phenyl 2-EtO-fer.il-CONH 1-266 COOH Phenyl 4-Me_NSC.-phenyl-CONH 1-267 COOH Phenyl 2-Cl-fer.il-S0NH 1-268 COOH Phenyl 4-NC_-fer.il-SO_NH 1-269 COOH Phenyl 4-Me: NSC_-phenyl-CONH 1-270 COOH Phenyl 4-Me.NSC.-phenyl-CONH 1-271 COOH Phenyl 4-P? RidiI-CONH 1-272 COOH Phenyl 4-?? rid? L-CONH I - 273 COOH Phenyl 4-Me2NS02-phenyl-CONH I - 274 COOH Phenyl 4-Me2NS02-phenyl-CONH I - 275 COOH Phenyl 4-N02-phenyl-S02NH I - 276 COOH Phenyl 3-N02-phenyl-S0NH I - 277 COOH Phenyl 4-Me2NS0-phenyl-CONH I - 278 COOH Phenyl 4-Me2NS02-phenyl-CONH I - 279 COOH Phenyl 4-Pyridyl-CONH I - 280 COOH Phenyl 4-Pyridyl-CONH I - 281 COOH Phenyl 4-Me2NS02-phenyl-CONH I - 282 COOH Phenyl 4-Me2N-phenyl-CONH I - 283 COOH Phenyl 4-N0-phenyl-S0NH I - 284 COOH Phenyl 4-N02-phenyl-SO.NH I - 285 COOH Phenyl 4-Me2N-pheny1-CONH I - 286 COOH Phenyl-MeN-phenyl-CONH I - 287 COOH 4-OMe-Phenyl 3-Pyridyl-CONH I - 288 COOH Phenyl 3-Pyridyl-CONH I - 289 COOH Phenyl 4-Me2N-phenyl-CONH I - 290 COOH Phenyl 4-Me2N-phenyl-CONH I - 291 COOH Phenyl 4-OMe-phenyl-SO.NH I - 292 COOH 3-Cl-Phenyl 4-Me 2 N -phenyl-CONH I - 293 COOH Phenyl 4-SH-phenyl-CONH I - 294 COOH Phenyl 3-Pyridyl-CONH I - 295 COOH 4-F-Phenyl 3-Pyridyl-CONH I - 296 COOH Phenyl 4-SH-phenyl-CONH I - 297 COOH Phenyl 3-SH-phenyl-CONH 1-298 COOH Phenyl 4-OMe-phenyl-S0 NH 1-299 COOH Phenyl 4-SH-phenyl-CONH 1-300 COOH Phenyl 3, 5-Di-OCF3-phenyl-CONH 1-301 COOH Phenyl 3, 5-Di-OCF -_-phenyl-CONH 1-302 COOH Phenyl 3-SH-phenyl-CONH 1-303 COOH Phenyl 5-OMe-3-Pyridyl-CONH 1-304 COOH Phenyl 4-OMe-3-Pyridyl-CONH 1-305 COOH 3-Cl-Phenyl 4-SH-phenyl-CONH 1-306 COOH Phenyl 3-Me; N-phenyl-CONH 1-307 COOH Phenyl 4-OMe-phenyl-SO.NH 1-308 COOH Phenyl 2-Cl-phenyl-CONH 1-309 COOH Phenyl 2-Cl-phenyl-CONH 1-310 COOH Phenyl 4-Cl-3-Pyridyl-CONH 1-311 COOH Phenyl 5-F-3-Pyridyl-CONH 1-312 COOH Phenyl 2-Cl-phenyl-CONH 1-313 COOMe Phenyl 3, 5-Di-OCF_-phenyl-CONH 1-314 COOH Phenyl 3, 5-Di-OCF3-phenyl-CONH 1-315 COOH Phenyl 2-Cl-phenyl-CONH 1-316 COOH Phenyl 4-OMe-phenyl-S02NH 1-317 COOH Phenyl 2-F-phenyl-CONH 1-318 COOH Phenyl 2-F-phenyl-CONH 1-319 COOH Phenyl 4-CN-3-Pyridyl-CONH 1-320 COOH Phenyl 4-F-3-Pyridyl-CONH 1-321 COOH 4-OMe-Phenyl 2-F-phenyl-CONH 1-322 COOH Phenyl 3-OMe-OCF 3 -phenyl-CONH I - 323 COOH Phenyl 3, 5-Di-OMe-phenyl-CONH I - 324 COOH Phenyl 2-F-phenyl-CONH I - 325 COOH Phenyl 2-OMe-phenyl-CONH I - 326 COOH 4-F-Phenyl 0 3, 5-Di-OMe-phenyl-CONH I - 327 COOH Phenyl 3, 5-Di-OMe-phenyl-CONH I - 328 COOH Phenyl 2-OMe-phenyl-CONH I - 329 COOH Phenyl 3-OMe-4-Pridyl-CONH I - 330 COOH Phenyl 3-OMe-4-Pridyl-CONH I - 331 COOH Phenyl 2-OMe-phenyl-CONH I-332 COOH 4-OMe-Phenyl 2-OMe-phenyl-CONH I - 333 COOH Phenyl 4-OMe-phenyl-S02NH I - 334 COOH Phenyl 2-OMe-phenyl-CONH I-335 COOH 4-F-Phenyl 3, 5-Di-OMe-phenyl-CONH I - 336 COOH Phenyl 3, 5-Di-OH-phenyl-CONH I - 337 COOH Phenyl 3, 4-Di-F-phenyl-CONH I - 338 COOH Phenyl 4-OMe-3-Pyridyl-CONH I - 339 COOH Phenyl 5-Cl-3-Pyridyl-CONH I - 340 COOH Phenyl 3, 4-Di-F-phenyl-CONH I - 341 COOH Phenyl 3, 4-Di-F-phenyl-CONH No. W X Q Y Z I - 1 CH C-OMe N C-OMe N I - 2 N C-Me CH C-Me N I - 3 N C-Me CH C-OMe N I - 4 N C-Ethyl N C-Ethyl N I - 5 N C-OMe N C-OMe N 1-6 N C-Ethyl CH C-Ethyl N 1-7 N C-Ethyl N C-Ethyl N 1-8 N C-Me CH C-Me N 1-9 N C-OMe CH C-OMe N 1-10 N C-Me CH C-Me N 1-11 N C-Me N C-Me N 1-12 N C-Ethyl N C-Ethyl N 1-13 N C-Me CH C-Me N 1-14 N C-OMe CH C-Me N 1-15 CH C-OMe N C-Me N 1-16 CH C-Me N C-Me N 1-17 N C-OMe CH C-OMe N 1-18 CH C-OMe N C-Me N 1-19 N C-Ethyl N C-Ethyl N 1-20 N C-Me CH C-Me N 1-21 N C-OMe CH C-Me N 1-22 N C-Ethyl N C-Ethyl N 1-23 CH C-OMe N C-OMe N 1-24 N N C-Me C-OMe N 1-25 N C-Me N C-Me N 1-26 N C-O - CH2-CH2-C C-OMe N 1-27 N C-Me CH C-Set N 1-28 N C-Me CH C-Me N 1-29 N C-O - CH2-CH2-C C-Me N 1-30 N C-OMe C-Me CH N 1-31 CH C-OMe CH C-Me N 1-32 N C-Me CH C-Me N 1-33 CH C-Me N C-OMe N 1-34 N C-Me CH C-CF-3 N 1-35 N C-OMe CH C-OMe N 1-36 N C-Me CH C-Me N 1-37 N C-OMe N C-Ethyl N 1-38 N N C-OMe C-Ethyl N 1-39 N C-OMe CH C-Ethyl N 1-40 N C-Me C-CN C-Oet CH 1-41 N C-OMe CH C-OMe N 1-42 N C-Ethyl CH C-Me • N 1-43 N C-OMe CH C-Me N 1-44 N C-Ethyl CH C-SMe N 1-45 N C-OMe CH C-OMe N ' 1-46 N C-Me CH C-Me N 1-47 N C-OMe CH C-OMe N 1-48 N C-Me CH C-Me N 1-49 N C-Ethyl N C-Ethyl N 1-50 N C-O - CH2-CH2-C C-Me N 1-51 N C-OMe CH C-OMe N 1-52 N C-O - CH2-CH2-C C-Me N 1-53 CH C-OMe N C-Me N 1-54 N C-O - CH2-CH2-C C-Me N 1-55 N C-OMe CH C-Me N 1-56 N C-Ethyl N C-Ethyl N 1-57 N C-Me CH C-Me N 1-58 CH C-Me N C-Me N 1-59 N C-CH 2 -CH. _-CH¿- -c C-Me N 1- 60 N C-Me CH C-Me N 1- 61 N C-OMe CH C-OMe N 1- 62 N C-Me CH C-Me N 1-63 N C-Me CH C-Me N 1- 64 N C-CH 2 -CH 2"CH 2 - • c C-Me N 1-65 N C-OMe CH C-OMe N 1-66 N C-Me CH C-Me N 1-67 N C-OMe CH C-Me N 1- 68 N C-CH 2 -CH 2 -CH 2 - -C C-OMe N 1- 69 N C-OMe CH C-Me N 1-70 N C-Ethyl N C-Ethyl N 1-71 N C-OMe CH C-OMe N 1-72 N C-Me CH C-Me N 1-73 N C-Me N C-Me N 1-74 N c-o- CH2- CH2-C C-OMe N 1-75 N C-Me CH C-NHMe N 1- 76 N C-OMe CH C-Me N 1-77 N c-o- CH2- CH2-C C-Me N 1 - . 1 - 78 CH C-OMe N C-Me N 1-79 N C-CH 2 -CH 2"CH 2 - -c C-OMe N 1- 80 N C-O- CH2- CH2-C C-OMe N 1-81 CH C-OMe N C-OMe N 1-82 N N C-OMe C-Me N 1-83 N C-O - CH2-CH2 - c C-Me N 1-84 N C-Me 'CH C-Me N 1-85 N C-Me N C-Me N 1-86 N C-Ethyl N C-Ethyl N 1-87 N C-O - CH, - • CH2 - c C-Me N 1-88 N N C-OMe C-Phenyl N 1-89 N C-OMe CH C-OMe N 1-90 N C-OMe CH C-OMe N 1-91 N C-Me CH C-Me N 1-92 N C-OMe CH C-Me N 1-93 N C-Me CH C-Me N 1-94 C-Ethyl N C-? Tyl N 1-95 N C-OMe CH C-OMe N 1-96 N C-Me CH C-Me N 1-97 N C-O - CH2 - CH2 - c C-Me N 1-98 CH C-OMe N C-Me N 1-99 N C-Me N C-Me N 1-100 N C-OMe CH C-OMe N 1-101 N c-o - CH2 - CH2 - c C-Me N 1-102 N C-Me CH C-Me N 1-103 CH C-OMe N C-Me N 1-104 N C-Ethyl N C-Ethyl N 1-105 N C-OMe CH C-OMe N 1-106 N C-Me CH C-Me N 1-107 CH C-OMe N C-OMe N 1-108 N C-Me CH C-Me N 1-109 N C-OMe CH C-Me N 1-110 N C-Ethyl N C-Ethyl N 1-111 N C-O - CH, -CH2-C C-Me N 1-112 N C-OMe CH C-OMe N 1-113 N "C-Me CH C-Me N 1-114 N C-O - CH2-CH _-- c C-OMe N 1-115 N C-OMe CH C-Me N 1-116 N C-Ethyl CH C-OMe N 1-117 N C-O-CH; -CH 2 -c C-OMe N 1-118 N C-OMe CH C-OMe N 1-119 N C-O - CH_- H. ' C-Me N 1-120 N C-Ethyl N C-Ethyl N 1-121 N C-Me CH C-Me N 1-122 N C-OMe CH C-Me N 1-123 N C-OMe CH C-OMe N 1-124 N C-Me N C-Me N 1-125 N C-Ethyl N C-ethyl N 1-126 N C-Me CH C-Me N 1-127 CH C-Ethyl N C-OMe N 1-128 N C-Me CH C-Me N 1-129 N c-o - CH2 - CH2 -c C-OMe N 1-130 N C-OMe CH C-OMe N -131 N C-OMe CH C-Me N 1-132 N C-Me CH C-Me N 1-133 N C-Me CH C-Me N 1-134 N C-OMe CH C-Me N 1-135 N C-Eti lo N C-NHMe N 1-136 N N C-Eti lo C-OMe CH 1-137 N C-Eti lo N C-Ethyl N 1-138 N C-Me CH C-Me N 1-139 N C-0-CH2-CH2-C C C - MMee N 1-140 N C-Ethyl CH C-OMe N 1-141 N C-OMe CH C-OMe N 1-142 N C-Me CH C-Me N 1-143 N C-OMe CH C-OMe N 1-144 N C-Me CH C-Me N 1-145 N C-OMe CH C-OMe N 1-146 N C-Me CH C-Me N 1-147 N N CH C-Me N 1-148 N C-OMe CH C-Me N 1-149 N C-OMe CH C-Me N 1-150 N C C - EEttiilloo NN C-Ethyl N 1-151 N C-0-CH: -CH2-C C-Me N 1-152 N C-Ethyl N C-Ethyl N 1-153 N C-Me CH C-Me N 1-154 N C-0-CH; -CH2-C C-OMe N 1-155 CH C-Me N C-OMe CH -156 N C-OMe CH C-OMe N 1-157 N C-O- CH2-CH-C-OMe N 1-158 N C-OMe CH C-OMe N 1-159 N C-CMe CH C-OMe N 1-160 N C-Me CH C-NMe N 1-161 N C-Me CH C-Me N 1-162 N C-OMe CH C-Me N 1-163 CH C-OMe N C-OMe N 1-164 N C-CH: -CH.-CH.-C C-Me 1-165 N C-? Tyl N c-Ethyl V 1-166 N C-Me CH C-Me N 1-167 N C-OMe CH C-Me \ " 1-168 N C-CMe CH C-OMe \ - 1-169 N C-3Me CH C-OMe \ - 1-170 N C-Me CH C-Me \ - 1-171 N C-DMe CH C-OMe V 1-172 N C-O- -CH_- CH.-C C-Me \ * 1-173 N C-OMe CH C-Me N 1-174 N C-? Tyl N C-Ethyl N 1-175 N C-Me N C-OMe N 1-176 CH C-OMe N C-Me N 1-177 N C-Me CH C-Me N 1-178 N C-0 -CH - CH2-C C-OMe N 1-179 N C-? Til N C-Etil X 1-180 N C-? Til CH C-OMe X 1-181 N c-o- -CH2- CH.-C C-OMe N 1-182 N C-OMe CH C-OMe N 1-183 N C-OMe CH C-Me N 1-184 N C-Me CH C-Me N 1-185 N C-Me CH C-Me N 1-186 N C-OMe CH C-Me N 1-187 N C-OMe CH C-OMe N 1-188 N C-OMe CH C-OMe N 1-189 N C-Ethyl N C-Ethyl N 1-190 N C-Me N C-Me N 1-191 N c-s- -CH2- CH2-C C-OMe N 1-192 N C-OMe CH C-OMe N 1-193 N c-o- -CH_- -CH: -C C-OMe N 1-194 N C-Me CH C-CF: N 1-195 N C-Me CH C-Me N 1-196 N C-OMe CH C-Me N 1-197 N N C-Me C-Me CH 1-198 N C-Ethyl N C-Ethyl N 1-199 N C-Me CH C-Me N 1-200 N C-Ethyl N C-Ethyl N 1-201 N C-Me N C-Me N 1-202 CH C-OMe N C-Me N 1-203 CH C-Me N C-NME2 N 1-204 N C-OMe N C-OMe N 1-205 CH C-Me N C-Me N 1-206 CH C-OMe N C-OMe N 1-207 N C-Me CH C-Me N 1-208 N C-OMe CH C-OMe N 1-209 N N C-Me C-OMe N 1-210 CH C-OMe CH C-Me N 1-211 N C-CE L-CH.-CH.-C C-Me N 1-212 CH C-Me N C-SMe N 1-213 N C-Me CH C-Me N 1-214 N C-Me CH C-Me N 1-215 N C-Me CH C-Me N 1-216 N C-Ethyl CH C-Ethyl N 1-217 N C-OMe C-CN C-OEt CH 1-218 N C-OMe CH C-OMe N 1-219 N C-OMe CH C-Me N 1-220 N C-Ethyl CH C-Me N 1-221 N C-Me CH C-Me N 1-222 N C-O- • CH.-CH-C C-OMe N 1-223 N c-o - CH.-CH.-C C-Me N 1-224 CH C-OMe N C-O-Me N 1-225 N C-OMe CH C-OMe N 1-226 CH C-Me N C-Me N 1-227 N C-OMe CH C-OMe N 1-228 CH C-Me N C-Cl CH 1-229 N C-OMe CH C-Me N 1-230 N C-Me CH C-Me N -231 N C-O - CH_-CH2 - c C-OMe N 1-232 N C-Me CH C-Me N 1-233 N C-OMe CH C-OMe N 1-234 N c-o - CH: -CH _-- c C-OMe N 1-235 N C-OMe C-F C-OMe N 1-236 N C-Ethyl N C-Ethyl N 1-237 N C-Me CH C-Me N 1-238 N C-OMe CH C-Me N 1-239 N C-OMe CH C-OMe N 1-240 N N CH C-Me N 1-241 N C-Ethyl N C-Ethyl N 1-242 N c-o - CH.-CH. ' -c C-OMe N 1-243 CH C-SMe N C-Me N 1-244 N C-OMe CH C-OMe N 1-245 N C-OMe CH C-OMe N 1-246 N C-Me CH C-Me N 1-247 N C-OMe CH C-OMe N 1-248 N C-Me CH C-Me N 1-249 N c-o - CH-CH2 -c C-Me N 1-250 N C-Me CH C-Me N 1-251 N C-Me C-CF3 N CH 1-252 N C-O-CH2-CH2-c C-OMe N 1-253 N C-OMe CH C-OMe N 1-254 N N C-Ethyl C-OMe N 1-255 N C-CH-CH-CH- • C C-OMe N 1-256 N C-O - CH2-CH2-C C-OMe N 1-257 N C-OMe CH C-OMe N 1-258 N C-Me CH C-Me N 1-259 N C-OMe CH C-SMe N 1-260 N C-Ethyl CH C-Ethyl N 1-261 N C-OMe CH C-Me N 1-262 N C-Ethyl N C-Ethyl N 1-263 CH C-Me N C-SMe N 1-264 N N C-OEt C-Me N 1-265 N C-Me CH C-Me N 1-266 N C-OMe CH C-OMe N 1-267 N C-OMe CH C-OMe N 1-268 N C-Me CH C-OMe N 1-269 N C-Me CH C-Me N 1-270 N C-OMe CH C-Me N 1-271 N C-Me CH C-Me N 1-272 N C-OMe CH C-OMe N 1-273 N C-Ethyl N C-Ethyl N 1-274 N C-Ethyl N C-Me N 1-275 N C-Me CH C-Me N 1-276 N C-Me N C-Me N 1-277 N C-CH2-CH-CH- • C C-Me N 1-278 CH C-CF3 N C-Me N 1-279 N C-O - CH-CH-C C-Me N 1-280 N C-Me CH C-SMe N 1-281 CH C-OMe N C-F CH 1-282 N C-OMe CH C-OMe N 1-283 N C-OMe C-Ethyl N CH 1-284 CH C-Ethyl N C-Ethyl N 1-285 N N CH C-Me N 1-286 N C-OMe CH C-Me N 1-287 N C-OMe CH C-OMe N 1-288 N C-O - CH2-CH-C C-Me N 1-289 CH C-Ethyl N C-Ethyl N 1-290 N C-Me N C-Me N 1-291 N C-Ethyl CH C-OMe N 1-292 N C-Me CH C-Me N 1-293 N C-Me CH C-Me N 1-294 N C-Me CH C-Me N 1-295 CH C-Me N C-OMe N 1-296 N C-Ethyl CH C-Ethyl N 1-297 N C-OMe CH C-Me N 1-298 N C-OMe CH C-OMe N 1-299 CH C-Ethyl N C-? Tyl N 1-300 N C-Me CH C-OMe N 1-301 N C-Me CH C-Me N 1-302 N C-Me N C-Me N 1-303 N C-Me CH C-Me N 1-304 N C-Me CH C-Me N 1-305 N C-Me CH C-Me N 1-306 N C-O-CH-CH2-C C-OMe N 1-307 CH C-Me N C-OBt CH 1-308 N C-CH: 2-CH2-CH-C C-Me N 1-309 N C-OMe CH C-OMe N 1-310 N C-Me CH C-Me N 1-311 N C-OMe CH C-OMe N 1-312 N C-Me CH C-Me N 1-313 CH C-OMe N C-Me N 1-314 N C-Ethyl N 'C-? Thio N 1-315 N C-Ethyl N C-Me N 1-316 N C-OMe CH C-OMe N 1-317 CH C-OMe N C-Etiic N 1-318 N C-Me CH C-Me N 1-319 N N CH C-Me N 1-320 N C-Me CH C-OMe N 1-321 N C-OMe CH C-Me N 1-322 N C-OMe CH C-OMe N 1-323 N C-Me CH C-Me N 1-324 N C-OMe N C-Ethyl N 1-325 N C-Ethyl CH C-Me N 1-326 N C-OMe CH C-Me N 1-327 N C-Ethyl N C-Ethyl N 1-328 N C-OMe CH C-OMe N 1-329 N C-Me CH C-Me N 1-330 CH C-OMe N C-Me N 1-331 N C-Me CH C-Me N 1-332 N C-OMe CH C-Me N 1-333 CH C-Ethyl N C-Ethyl N 1-334 CH C-OMe N C-Ethyl CH 1- 335 N C-Ethyl CH C-NHMe N 1-336 N C-Me CH C-Me N 1-337 N C-OMe CH C-OMe N 1-338 N C-Ethyl N C-Ethyl N 1-339 N C-OMe CH C-OMe N 11--334400 NN CC - MMee CH C-Me N 1-341 N C-OMe CH C-Me N Example 14: Data of receptor binding were measured for 1 compounds appearing in the following list using the test described above. The results appear in table 2. Table 2 Receiver link data (K values) Compound ET ^ [nM] ETE [nM] 1-4 74 2100 1-48 67 1400 1-66 63 > 3000 1-156 337 > 10000 1-170 140 4600 1-199 99 3400 -201 84 5500 -248 18 930 -294 52 6700 -340 225 5400

Claims

CLAIMS 1. A β-amido or β-sulfonamido derivative of carboxylic acid of the formula I wherein the substituents have the following meanings: R ^ is tetrazolyl or a group C-RR: a radical OR ', where R ° is: hydrogen, C3-C cycloalkyl ?, C-C = alkyl, CH: phenyl, it being possible for said radicals to be optionally substituted, C3-C3 alkenyl group OR optionally substituted C3-C alkynyl group or optionally substituted phenyl, b) a 5-membered heteroaromatic system linked to through a nitrogen atom, a group wherein k can take the values 0, 1 and 2, p can take the values 1, 2, 3 and 4, and R 'is alkyl C.-C;, C3-C3 cycloalkyl, C_-C = alkenyl, C3 alkynyl -C; or optionally substituted feryl, d) an O radical II -N S- R * H ¡I o wherein Rd is: C-C-C3-C3-alkenyl, C-C-C3-alkynyl, C-C3-cycloalkyl, it being possible for these radicals to carry a C-C4-alkoxy radical, C-C4-alkylthio and / or a radical phenyl, haloalkyl C-C; or phenyl, optionally substituted, W and Z, which may be identical or different: nitrogen or methine; provided that Q = nitrogen if W and Z = methine; X is nitrogen or CR '; And it's nitrogen or CR "; ' Q is nitrogen or CR_i; provided that X = CR 'and Y = CR' 'if Q = nitrogen; R "and R ~, which may be identical or different, are: phenyl or naphthyl, optionally substituted, or phenyl or naphthyl joined together in ortho positions through a direct bond, a methylene group, ethylene or ethenylene, an oxygen or sulfur or an S02, NH or N-alkyl group; C-C5 cycloalkyl, optionally substituted; R4 a) a radical wherein R: is phenyl, naphthyl or a five or six member heteroaromatic system comprising one to three nitrogen atoms and / or a sulfur or oxygen atom, it being possible for these radicals to be optionally substituted; b) a radical O II -SR "II or wherein R 3 is C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, phenyl or phenoxy, it being possible for the phenyl radicals to be optionally substituted; Rs is hydrogen, alkyl Cj.-C; R "and R" ° (which may be identical or different) are: hydrogen, halogen, C1-C4 alkoxy, C2-C4 haloalkoxy, C3-Ce alkenyloxy, C-Cd alkynyloxy, C2-C4 alkylthio, C-C4 alkylcarbonyl, C4-C4 alkoxycarbonyl, hydroxyl, NH2, NH (C1-C4 alkyl), N (C2-C2) alkyl, C: -C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, it being possible for these radicals to be optionally substituted; or CR "" 'or CR1' "'is attached to CR" in accordance with what is indicated below to provide a ring of 5 or 6 members, 'R' is hydrogen, halogen, C -.- C-, C2-C4 haloalkoxy, C3-C6 alkenyloxy, C3-C8 alkynyloxy, C -.- C alkylthio, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl -C 4, NH (C 1 -C 4 alkyl), N (C 1 -C 4 alkyl) 2, hydroxyl, carboxyl, cyano, amino, mercapto; C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, it being possible for these radicals to be optionally substituted; either or CR "" form together with CR: 'or CRiC a ring of 5 or 6 membered alkylene or alkenylene, which may be optionally substituted and wherein in each case one or more methylene groups may be replaced by oxygen, sulfur, -NH or -N (C

1 -C 4 alkyl), and the salts physiologically tolerated, and the possible enantiomerically pure and diastereomerically pure forms, except the following compounds: 2- (6-ethyl-2-methyl-4-pyrimidinyloxy) -3- (4-methoxybenzoylamine) -3,3-diphenylpropionic acid 2 - (2,6-dimethyl-4-pyrimidinyloxy) -3- (4-methoxybenzoylamino) -3,3-diphenylpropionic acid 3- (4-methoxybenzoylamino) -2- (6-methoxy-2-methyl-4-pyrimidinyloxy) -3,3-diphenylpropionic acid 3- (4-methoxybenzolamino) -2- (6-methoxy-5-methyl-2-pyrazinyloxy) -3,3-diphenylpropionic acid 3- (4-methoxybenzoylamino) -2- ( 5-methoxy-6-methyl [1,2,4] -triazin-3-yloxy) -3,3-diphenylpropionic acid 2- (4-ethyl-6-methyl [1,3,5] triazin-2-yloxy ) -3- (4-methoxybenzoylamino) -3,3-diphenylpropionic acid 3- (4-methoxybenzoylamino) -2- (5-methoxy-6-methyl-3-pyridazinyloxy) -3,3-diphenylpropionic acid 2- (4,6-dimethyl [1,3,5] triazin-2-yloxy) -3- (4- methoxybenzoylamino) -3,3-diphenylpropionic acid 3- (4-methoxybenzoylamino) -2- (4-methoxy-6-methyl [1, 3, 5] -triazin-

2-yloxy) -3,3-diphenylpropionic acid

3- (

4-methoxybenzoylamino) -2- (4-methoxy-6,7-dihydro-5H-cyclopentapyrimidin-2-yloxy) -3,3-diphenylpropionic acid 3- (4-methoxybenzoylamino) -2- (4- methoxy-5,6-dihydrofuro [2,3-d] pyrimidin-2-yloxy) -3,3-diphenylpropionic acid 2- (4,6-dimethoxy-2-pyrimidinyloxy) -3- (4-methoxybenzoylamino) -3 , 3-diphenylpropionic acid 2- (4-ethyl-6-methyl-2-pyrimidinyloxy) -3- (4-methoxybenzoylamino) -3,3-diphenylpropionic acid • 2- (4,6-dimethyl-2-pyrimidinyloxy) - 3- (4-methoxybenzoylamino) -3,3-diphenylpropionic acid 3- (4-methoxybenzoylamino) -2- (4-methoxy-6-methyl-2-pyrimidinyloxy) -3,3-diphenylpropionic acid 2- (4,6) -dimethyl-2-pyrimidinyloxy) -3- (4-hydroxybenzoylamino) -3,3-diphenylpropionic acid 2- (4-methoxy-6-methyl-2-pyrimidinyloxy) -3- (4-methylsulfonylbenzoylamino) -3, 3- diphenylpropionic acid 2- (4,6-dimethoxy-2-pyrimidinyloxy) -3- (4-nitrobenzoylamino) -3,3-diphenylpropionic acid 3- (4-chlorobenzoylamino) -2- (4-ethyl-6-methyl-2) -pyrimidinyloxy) -3,3-diphenylpr 3- (4-ethylbenzoylamino) -2- (4-methoxy-6,7-dihydro-5H-cyclopentapyrimidin-2-yloxy) -3,3-diphenylpropionic acid 3, 3-bis- (4-fluorophenyl) acid 3- (4-methoxy-benzoylamino) -2- (4-methoxy-5,6-dihydrofuro [2,3-d] pyrimidin-2-yloxy) -propionic acid 3- (4-chlorobenzoylamino) -2- (4 , 6-dimetii [1, 3, 5] triazin-2- iloxy) -3,3-diphenylpropionic acid 3- (3,4-dimethoxybenzoylamino) -2- (4-methoxy-6-methyl- [1,3,5] triazin-2-yloxy) -3,3-diphenylpropionic acid 3- (3, 4-dimethoxybenzoylamino) -2- (4-ethyl-o-methyl- [1,3,5] triazin-2-yloxy) -3,3-diphenylpropionic acid 3- (4-chlorobenzoylamino) -2 - (

5-methoxy-

6-methyl-3-pyridazinyloxy) -3,3-diphenylpropionic acid 3- (3,4-dichlorobenzoylamino) -2- (6-methoxy-5-methyl-2-pyrazinyloxy) -3,3 -diphenyl propionic acid 3- (4-hydroxy-3-methoxybenzoylamino) -2- (5-methox? -6-methyl [1, 2,4] triazin-3-yloxy) -3,3-diphenylpropionic acid 3- (3 -chlorobenzoylamino) -2- (2,6-d? meth? l-4-pyrimidinyloxy) -3,3-diphenylpropionic acid 3- (2-chlorobenzoylamino) -2- (6-methoxy-2-met? l-4) -pyrimidinyloxy) -3,3-diphenylpropionic acid 2- (6-ethyl-2-methyl-4-pyrimidinyl-cxy) -? - (4-nitrobenzoylamino) -3,3-diphenylpropionic acid. 2. The use of the β-amido and β-sulfonamide carboxylic acid derivatives according to claim 1 for the treatment of diseases. 3. The use of compounds I of conformity ccr. claim 2 as endothelin receptor antagonists. 4. The use of the β-amido and β-sulfonamide carboxylic acid derivatives I in accordance with claim 1 the production of drugs for the treatment of diseases in which high levels of endothelin occur. The use of the β-amido and β-sulfonamido derivatives of carboxylic acid I according to claim 1 for the treatment of chronic heart failure, restenosis, high blood pressure, pulmonary hypertension, acute / chronic renal failure, erectile dysfunction, ischemia cerebral, benign prosthetic hyperplasia as well as prostate cancer. The use of the β-amido and β-sulfonamido derivatives of carboxylic acid I according to claim 1 in combination with: inhibitors of the renin-angiotensin system such as, for example, renin inhibitors, angiotensin II antagonists, and, particularly , angiotensin-converting enzyme (ACE) inhibitors; ECA / mixed neutral (NEP) endopeptidase inhibitors; beta-blockers. A pharmaceutical preparation for oral, parenteral and intraperitoneal administration containing at least one carboxylic acid derivative I according to claim 1 with a single dose, in addition. of conventional auxiliary pharmaceutical substances. A compound of formula II II wherein the radicals R *, R ", R ', R: and R" have the meanings set forth in claim 1. 9. The use of compounds of the formula II, R4 R2 B 1 C- OH / R5 R3 Rl II wherein the radicals R ~, R ", R", R "and R" have the meanings set forth in claim 1, as the starting material for synthesizing antagonists of endothelial receptors. 10. A structural fragment of the formula wherein the radicals R1, R ~, R3, R4 and RD have the meanings set forth in claim 1, as a structural element in an endothelin receptor antagonist.